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ABSTRACT OF DISSERTATION

INSULIN ACTIONS ON HIPPOCAMPAL NEURONS
Aging is the main risk factor for cognitive decline. The hippocampus, a brain
region critical for learning and memory formation, is especially vulnerable to
normal and pathological age-related cognitive decline. Dysregulation of both
insulin and intracellular Ca2+ signaling appear to coexist and their compromised
actions may synergistically contribute to neuronal dysfunction with aging. This
dissertation focused on the interaction between insulin, Ca2+ dysregulation, and
cognition in hippocampal neurons by examining the contributions of insulin to
Ca2+ signaling events that influence memory formation. I tested the hypothesis
that insulin would increase cognition in aged animals by altering Ca2+dependent physiological mechanisms involved in learning. The possible effects
of insulin on learning and memory in young and aged rats were studied. In
addition, the effects of insulin on the Ca2+-dependent afterhyperpolarization in
CA1 pyramidal hippocampal neurons from young and aged animals were
compared. Further, primary hippocampal cultures were used to examine the
possible effects of insulin on voltage-gated Ca2+ channel activity and Ca2+induced Ca2+-release; mechanisms known to influence the AHP.
We found that intranasal insulin improved memory in aged F344 rats. Young and
aged F344 rats were treated with Humalog®, a short-acting insulin analog, or
Levemir®, a long-acting insulin analog. The aged rats performed similar to young
rats in the Morris Water Maze, a hippocampal dependent spatial learning and
memory task. Electrophysiological recordings from CA1 hippocampal neurons
revealed that insulin reduced the age-related increase in the Ca2+-dependent
afterhyperpolarization, a prominent biomarker of brain aging that is associated
with cognitive decline. Patch clamping recording from hippocampal cultured
neurons showed that insulin reduced Ca2+ channel currents. Intracellular Ca2+
levels were also monitored using Fura-2 in response to cellular depolarization.
Results indicated that a reduction in Ca2+-induced Ca2+-release from
intracellular stores occurred in the presence of insulin.
These results suggest that increasing brain insulin levels in aged rats may have
improved memory by reducing the AHP and intracellular Ca2+concentrations.
This study indicates a possible mechanism responsible for the beneficial effects

of intranasal insulin on cognitive function absorbed in selective Alzheimer’s
patients. Thus, insulin therapy may reduce or prevent age-related compromises
to Ca2+ regulatory pathways typically associated with cognitive decline.

KEY WORDS: Insulin, Aging, Cognition, Intracellular Ca2+, Ca2+ imaging,
Whole-cell patch clamping
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Chapter 1 Thesis Overview and Significance

Aging, an inexorable natural process, often presents many challenges ranging
from ambulatory to neuronal function. One of these challenges, age-related
cognitive decline has received significant public attention because of its profound
social and economic impact. A well-recognized mechanism contributing to agerelated cognitive decline involves dysregulation of intracellular calcium. Although
Insulin has been recognized as the key hormone regulating cellular glucose
metabolism, its downstream effects on learning and memory have only recently
been found. Some evidence suggests that insulin undergoes age-related
changes that ultimately influence calcium regulatory mechanisms in various
brain regions, including the hippocampus, an area of the brain closely related to
learning and memory. Thus, the negative impact of brain aging on cognitive
function may be due to impaired insulin signaling and intracellular calcium
homeostasis. However, the link between insulin and intracellular calcium in the
context of cognitive decline with aging is not understood. This dissertation
focused on the effects of insulin on memory and its underlying neuronal
mechanisms. I specifically focused on studying1) the effects of insulin treatment
on learning and memory in aged animals as well as 2) the effects of insulin on
intracellular calcium regulation. Understanding the links between insulin and
neuronal mechanisms involving hippocampal calcium processes may help
develop therapeutic strategies to decrease complications associated with agerelated cognitive decline.
1

1.1 Brain Aging and cognition
Aging leads to a function decline of many organs, including the brain. Age-related
changes in the brain such as reduced insulin signaling, reduced neuronal
glucose uptake, increased glucocorticoid levels, and increased intracellular
calcium concentration may give rise to pathological brain aging. One of the
hallmarks of brain aging is cognitive decline [1, 2]. Many factors could influence
the age-related decline of cognitive function, including dysfunctions of circadian
clock [3], and oxidative stress [4-9]. Growing evidence supports the concept that
brain insulin and calcium may play an important role in the mechanisms behind
memory decline in advanced age and Alzheimer’s disease (AD) [10-12]. At the
cellular level, brain insulin deficiency and insulin resistance may be one of the
fundamental

changes

associated

with

altered

memory

function

during

pathological aging [13-20]. Brain insulin signaling disruption has been closely
associated with cognitive decline and AD [14, 21-25]. At the receptor level, the
amount of insulin receptors and their functions are decreased in aging and AD
animal models [26-28]. At the clinical level, studies suggest that memory
improved in AD patients are due to changes in their insulin levels [29]. In aged
animals, it has also been shown that intranasal delivery of insulin to the central
nervous system (CNS) positively correlates with increased brain cognitive
function [30]. The intranasal route of insulin administration increases insulin
acutely in the brain without risk of peripheral hypoglycemia. Importantly, it
significantly enhances the memory in both aged and AD patients [31-35].
2

Although intranasal insulin enhances memory in AD patients, varying outcomes
arise with its clinical setting usage. Men and women with AD respond differently
to intranasal insulin dosage [36]. In addition, some clinical studies reported that
patients carrying at least one copy of the Apolipoprotein E4 (the strongest
genetic risk factor for late onset Alzheimer’s disease) did not benefit from
intranasal insulin treatment [37]. Therefore, gender and ApoE status in AD
patients increase outcome variability in intranasal insulin treatment. These
varying outcomes highlighted the need to understand the underlying neuronal
mechanism the effects of insulin on cognitive function with aging.

1.2 Insulin
Identifying the link between the pancreas and diabetes by Von Morning and
Minkowski in 1890 opened the door for the discovery of insulin as a therapy. This
life-sustaining hormone saved an enormous number of lives since its discovery. In
the early twentieth century, Sharpey-Schafer hypothesized that pancreas secretes
a hormone that controls glucose levels [38]. In 192, this hypothesis was confirmed
and a novel protocol to purify insulin was developed. In 1922, insulin therapy was
successful on a type 1 diabetic patient. Since the introduction of human insulin in
1982 and insulin analogs in 1996, insulin therapy become the standard treatment
options for diabetic patients [39, 40] by mimicking physiological insulin secretion in
the body to regulate blood glucose levels. After almost 100 years of research, it is
clear that Insulin is a natural peptide hormone secreted by the pancreatic β-cell in
3

response to elevated blood glucose concentration, and that it plays an
indispensable role in maintaining blood glucose concentration and regulating
metabolism [41]. In insulin therapy, to enhance the insulin’s effects and reduce
the number of injection different routes of insulin delivery, as well as different
insulin formulations were designed by combining insulin with zinc and/or basic
proteins protamine [42].

1.3 Zinc
Zinc is an essential ion involved in many physiological processes ranging from
cell proliferation to neuronal function. Zinc plays a critical role in regulating insulin
synthesis, storage, and secretion in the pancreatic beta cells [43-45]. Zinc
combined with insulin and induces proinsulin hexamerization, also co-releases
with insulin from the beta cells [46]. It is well documented that zinc, pancreatic
beta cell, and diabetes have a strong cause and effect relationship. Zinc is highly
abundant in the pancreatic islet and zinc deficiency has been associated with
diabetes [47]. High levels of zinc can be toxic to the cells, specifically to the
neurons [48, 49]. Zinc present in the brain with its highest concentration in the
olfactory bulb, hippocampus, hypothalamus, and cortex. Increased zinc stimulates
synaptic events via AMPA receptors and improves synaptic summation [50] and
influences LTP induction and memory [51].

1.4 Insulin formulations and alternative routes for insulin administration
4

Insulin formulations (Table 1.1), also different routes of insulin delivery (e.g.,
nasal, pulmonary inhaled, intravenous insulin infusion, insulin pumps) were
developed [52, 53]. Currently, insulin cannot take orally because it will break down
in stomach before it regulates glucose levels. Earlier research has focused on
understanding the molecular mechanism through which insulin regulates glucose
to uncovered insulin’s potential effects on memory enhancement. Although insulin
is effective and widely used, researchers continue to study the molecular
mechanisms by which insulin regulates glucose uptake in fat, muscle, and
neuronal cells to obtain even more benefits from this life-sustaining hormone.

5

Table 1. Insulin Types by Brand Name, Generic Name, Onset, Peak, and
Duration of Action.

Type of Insulin

Brand Name

_NovoLog
Rapid-Acting

_Apidra
_Humalog

Short-Acting
IntermediateActing

_Humulin R
_Novolin R
_Humulin N
_Novolin N
_Levemir

Long-Acting
_Lantus
Pre-mixed NPH
(Intermediateacting) and
regular (shortacting)

Pre-mixed
insulin lispro
protamine
suspension
(Intermediateacting) and
insulin lispro
(rapid-acting)
Pre-mixed
insulin aspart
protamine
suspension
(Intermediateacting) and
insulin aspart
(rapid-acting)

_Humulin
70/30,
_Novolin
70/30
_Humulin
50/50

_Humalog
Mix 75/25

_Humalog
Mix 50/50

_NovoLog
Mix 70/30

Generic Name

Onset

Peak

Duration

_Insulin
aspart
_Insulin
glulisine
_Insulin
lispro

15
minutes
15
minutes
15
minutes

30 to 90
minutes
30 to 90
minutes
30 to 90
minutes

3 to 5
hours
3 to 5
hours
3 to 5
hours

_Regular ( R)

30 to 60
minutes

2 to 4
hours

5 to 8
hours

_NPH (N)

1 to 3
hours

8 hours

12 to 16
hours

_Insulin
determir
_Insulin
glargine

1 hour

Peakless

20 to 26
hours

_70% NPH
and 30%
regular

30 to 60
minutes

Varies

10 to 16
hours

30 to 60
minutes

Varies

10 to 16
hours

10 to 15
minutes

Varies

10 to 16
hours

10 to 15
minutes

Varies

10 to 16
hours

5 to 15
minutes

Varies

10 to 16
hours

_50% NPH
and 30%
regular
_75% insulin
lispro
protamine
and 25%
insulin lispro
_50% insulin
lispro
protamine
and 50%
insulin lispro
_70% insulin
aspart
protamine
and 30%
aspart

6

1.5 Insulin signaling in the periphery
Insulin plays a vital role in maintaining blood glucose levels in the periphery.
Insulin in the muscle and fat tissues promote glucose uptake. Insulin stimulates
glucose storage, and inhibits glucose secretion in the liver [41, 54-61].
Insulin regulates glucose uptake in fat and muscle cells by inducing translocation
of glucose transporters to the plasma membrane [62-68] by PI3K/AKT pathway
[69]. Insulin also regulates glucose concentration via suppression of hepatic
glucose production (HGP) [61, 70, 71]. Previous studies suggest that insulin
regulates HGP by binding to the insulin receptor and activating serine/threonine
kinases AKT [72, 73], which further inhibits Foxo1 phosphorylation [74-76].
Therefore, insulin prevents large alteration in blood glucose levels during the day
by enhancing glucose metabolism in the cells and suppressing hepatic glucose
production.

7

Figure 1.1 Mechanisms of Insulin Actions in the Periphery.

In healthy individuals, blood glucose levels are tightly controlled by insulin, a
natural hormone produced by the pancreatic beta cells in response to high blood
glucose levels. In fat tissues, insulin increases triglyceride synthesis/ storage and
decreases triglyceride breakdown. In the liver, insulin increases glycogen
deposition

and

glucose

use

while

decreasing

glycogenolysis

and

gluconeogenesis. In muscle cells, insulin increases glucose uptake and protein
synthesis while decreasing protein degradation.

8

Insulin promotes glucose uptake by cells through four major glucose transporter
isoforms are widely distributed throughout the body. The glucose transporter 4
(Glut-4) is highly expressed in fat and muscle cells [77]; Glut-1 and Glut-2 are
expressed in the endothelial cells lining the blood vessels and liver, intestine,
kidney, pancreatic cells; and Glut-3 is expressed in the neurons [78]. When
insulin binds to the insulin receptors on the surface of target cells, it promotes
translocation of glucose transporters to the plasma membrane, which moves
glucose into the cell. Once glucose move inside the cell, it delivers energy to it.
Altered insulin levels, insulin receptors and/ or glucose transporters all can lead
to obesity, insulin resistance, and diabetes [79-83]. Although insulin is
recognized as glucose regulating hormone, it is increasingly clear now that
insulin also plays a critical role in the regulation of neuroplasticity,
neuromodulation,

neurotrophism,

neuronal

growth

and

survival

[84-92].

Therefore, insulin is important not only for regulating sugar, but also for learning
and memory. To initiate insulin signaling, insulin has to bind to the insulin
receptor and activates the insulin receptor tyrosine kinase.
Together with human insulin receptor characterizations, studies of insulin
receptor tyrosine kinase activity have enhanced our understanding of the
mechanisms of insulin action in various organs. Indeed, insulin acts on the fat,
muscle, liver, and brain through the insulin receptor substrate pathways.
9

Figure 1.2 Insulin signaling pathways and translocation of glucose transporter
(GLUT) to the plasma membrane by insulin.

To initiate insulin signaling, insulin must bind to insulin receptors on the plasma
membrane. Insulin receptors contain two α subunits outside the cell and two β
subunits inside the cell. α subunits have an insulin binding site, and β subunits
have a tyrosine kinase phosphorylation site. Once insulin binds to insulin
receptors, it triggers autophosphorylation of β subunits of insulin receptors, which
leads to phosphorylation of insulin receptor substrate (IRS), which further
phosphorylates PI3K and AKT. Next, downstream signaling pathways promote
translocation of glucose transporters (GLUT) to the plasma membrane, which
brings glucose inside the cell modified from [93].

10

1.6 Insulin signaling in the brain
While insulin plays an essential role in the brain, brain insulin itself is important for
regulating insulin secretion from the pancreatic beta cells [94]. Important actions
of insulin in the brain are now gradually becoming clear, even through the brain
has been considered an insulin-independent organ for several decades. Insulin
and insulin-like growth factor (IGF1-2) bind to insulin receptor and IGF-1R and
initiate insulin signaling. Insulin receptor and IGF-1R co-express in the brain and
share the intracellular signaling pathways; however, each of them has a unique
function. This view has been further tested using neuron-specific insulin receptor
and IGF-1R knockout mice. Deleting insulin receptors in the brain leads to mild
obesity and insulin resistance without influencing brain size and development [95].
However, deleting IGF-1R affects brain size and development and contributes to
behavior changes [96]. All the insulin receptor substrates (IRS1-4) present in the
brain, and IRS2 play a vital role in the brain since their deletion results in impaired
brain development [97, 98]. IRS mediate the phosphorylation of AKT/PI3K, which
further activates several downstream signaling pathways [99]. Insulin downstream
signaling promotes translocation of glucose transporters to the plasma
membrane both in peripheral and brain tissues [62-68, 77, 100, 101]. Taken
together, peripheral and brain insulin share similar signaling pathways.

11

Figure 1.3 Actions of insulin in the brain.

The brain has been traditionally considered insulin-insensitive. However, now it is
clear that normal brain functions depend on insulin, and insulin receptors are
widely expressed in the brain. Insulin activates insulin signaling via binding insulin
receptors and regulates various neuronal functions: it enhances learning and
memory and regulates energy homeostasis, whole body metabolism, body
temperature, mood, and appetite modified from [93].
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This year we are celebrating the 96th anniversary of the discovery of insulin by
Frederick Banting. Yet only over the past few years has interest increased in
brain insulin’s role in cognition, food intake, body weight, and whole-body
metabolism. Insulin in the brain has been detected at high levels in mouse
embryos (E9) at early developmental stages and reduces with age [102]. Insulin
receptors are located at brain synapses, and highly concentrated at the
postsynaptic density [103]. Therefore, insulin may regulate synaptic function and
excitatory synaptic transmission stability during neuronal development via insulin
receptors. Furthermore, the insulin receptor substrate 53 (highly expressed in the
postsynaptic density) also plays a role in regulating spine density in hippocampal
cultured neurons [104].

1.7 Insulin receptors in the brain vs. in the periphery
Insulin receptors belong to a tyrosine kinase family and activate through insulin
binding [105]. The insulin receptor is a dimeric transmembrane protein encoded
by a single gene, INSR, and alternative splicing of INSR gives rise to α and
β subunits. The insulin receptor is composed of two extracellular α subunits that
bind to insulin and two intracellular β subunits with tyrosine kinase activity [106].
Insulin binds to α subunits of the insulin receptor, leading to autophosphorylation
of β subunits and activating the receptor, which further phosphorylates and
recruits different substrate (IRS) adaptor proteins [41, 107]. Insulin and insulin
receptor signaling play an important role both in the periphery and the brain and
13

mediate many cell functions ranging from glucose metabolism to learning and
memory. Furthermore, insulin receptors are expressed in almost all tissues in the
body. However, researchers have found that the anti-insulin receptor that
blocked the insulin receptor in the periphery had no effect on brain insulin
receptors [108]. This study strongly supports that some structural and molecular
differences exist between the peripheral and brain insulin receptors. Moreover,
the difference between peripheral and brain insulin receptors is primarily due to
alternative mRNA splicing of the exon-11.
Brain insulin receptors lack exon-11, and therefore, brain insulin receptors have
smaller subunits compared to peripheral insulin receptors [108-111]. Brain insulin
receptors do not down-regulate in response to prolonged and/or a high
concentration of insulin exposure [112, 113]. Brain insulin receptors reduce with
aging and influence learning and memory, and learning improves insulin receptor
functions [28]. These studies along with studies from the NIRKO mice model (a
neuron-specific insulin receptor gene deletion [95] provide clear understanding of
role of brain insulin receptor in brain function (food intake, metabolism,
reproduction, cognition [114]. However, it is important to understand how insulin
gets into the brain.

14

1.8 Insulin synthesis in the brain
1.8.1 Peripheral source of insulin
It is widely believed that insulin is synthesized and released mainly from the
pancreatic beta cells in response to blood glucose levels.

Insulin is initially

synthesized as preproinsulin, and removal of its amino terminal single peptide
generates proinsulin. Excision of C peptide within the endoplasmic reticulum
gives rise to α (21 amino acids) and β (30 amino acids) of insulin. C peptide is a
biomarker of insulin secretion. Although various factors may influence insulin
secretion, one key factor is blood glucose level. When glucose concentration
rises, glucose moves into the cell by a glucose transport. Then, glucose is
metabolized to generate ATP, which blocks ATP- dependent K+ channels in the
beta cell membrane, which results in the depolarization of the cell. Depolarization
causes the Ca2+ ion channels to open, and Ca2+ ions to move in, which triggers
vesicles containing insulin to move to the membrane fuse, and release the
insulin by exocytosis.
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Figure 1. 4 The mechanism of insulin secretion by the pancreatic beta cell.

Increases in blood glucose levels trigger insulin release. Modified from Molecular
biology of the cell (3rd ed.) by Alberts B, et al., 1994.
1.8.2 Central source of insulin
Previous studies show that insulin produced by the pancreas could enter the
brain by crossing the blood brain barrier to maintain energy balance [107, 115120]. Furthermore, insulin permeability changes during aging and in patients
with diabetes and AD [121, 122]. Based on different experimental evidence, the
brain also produces its own supply of insulin [10]. In 1983, Dorn et al. confirmed
the hypothesis that part of the brain insulin is produced in the central nervous
system (CNS). Results from the study of human cadaver brains demonstrated
that insulin and C-peptide were present in most nerve cells [123]. Further, Cpeptide and insulin receptors in the brain decreased with aging [124]. Unlike
mammals, in drosophila and C.elegans, neurons are the primary cells to
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produce insulin

[99]. Together with animal studies and observations from

hippocampal cultured neurons studies, it is clear that insulin can be synthesized
locally in the brain and released from the neurons in response to depolarization
[125, 126]. While brain insulin and insulin receptor signaling undergo changes
with aging, insulin resistance may contribute to pathological brain aging [127133].
Insulin also is valuable for treating a wide variety of non-diabetic diseases, such
as schizophrenia, anxiety, nervousness, cancer, and cognitive function. While
insulin in the brain enhances learning and memory, insulin resistance is linked
to Alzheimer’s disease and other neurodegenerative disorders [134-136].
Currently, increasing insulin signaling in the brain is one of the best treatment
options to improve memory in aged and AD populations [137].

1.9 Metabolism and the brain
The brain is a complex organ and needs lots of energy to run properly [138].
Glucose is the main substrate that satisfies brain high-energy demands. The
brain (rich with neurons) weighs only 2% of body weight, but neurons use 25
percent of all the glucose energy in the body while its energy store capacity is
small. Hence, the brain requires a constant glucose supply from the blood, and
glucose is transported into the brain via the glucose transporters through the
blood brain barrier. Although the brain is an energy-intensive organ, it has
traditionally been considered insulin-insensitive. However, recently this view has
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been challenged, and now it is clear that normal brain function depends on
insulin. Moreover, brain functions such as learning and memory are positively
correlated with effective glucose metabolism in the brain. Dysregulation of brain
glucose metabolism can lead to loss of energy for brain functions, which further
influences the neurotransmitters, neuronal communication, and cognitive
function. Therefore, the traditional role of Insulin in the brain is regulating glucose
metabolism and enhancing neuronal survival. It is also known that insulin and
insulin receptors in the brain reduce with aging [124]. Additionally, the link
between metabolic disturbances and neurodegenerative diseases have been
well documented. Researchers have suggested that Alzheimer’s disease is
positively correlated with obesity and diabetes [16, 139-145]. Previous studies
suggest that type 2 diabetes increases the risk of developing AD [146-149]. Also,
some studies suggest that AD is a brain- specific form of diabetes (type 3
diabetes) [150-155]. Furthermore, clinical studies suggest that AD patients
present abnormal brain glucose metabolism [26, 156]. Normal brain glucose
metabolism is vital for brain function and controlled by brain insulin/insulin
receptor signaling pathways [157].
Insulin in the brain is the key to many neurological disorders. In fact, brain insulin
regulates both periphery and central glucose metabolism, learning, and memory
[87, 107, 158, 159]. Insulin exerts its effects though insulin receptors, which are
widely distributed in various regions of the brain

[107, 160-162]. More

specifically, insulin receptors are highly expressed in the hippocampus [107,
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163], a brain region that is critical in synaptic plasticity, learning, memory, and
cognition. Brain insulin and insulin receptor levels decrease with aging and AD,
which is linked to age-related memory impairment [152, 164-166]. Insulin
receptors are also expressed in the hypothalamus, the widely studied region of
insulin action in the brain. Insulin circulates at the level proportionate to body fat
mass, inhibits food intake through its actions on the hypothalamic neurons [167,
168], and regulates glucose metabolism [169] and energy expenditure [170] both
in the periphery and the brain [171]. The highest concentration of insulin and
insulin receptors are detected in the olfactory bulb [172, 173], and insulin
regulates olfactory functions, which are important for food intake and appetite
[174]. Insulin receptors are also present in the cerebral cortex and cerebellum
[28] and plays an important role for neuronal survival [158]. Furthermore, Kahn et
al created neuron-specific insulin receptor knockout mice (NIRKO) to study
insulin actions in the brain. The study results suggest that depletion of insulin
receptors in neurons lead to obesity and dysregulation of a reproduction
hormone [95]. Insulin has diverse effects in the brain. Insulin may promote better
nerve cell communication, but the disruption of brain insulin signaling may lead
to metabolic dysregulation and cognitive impairment [87, 134, 175]. Insulin has
also been viewed as the potential missing link between memory and intracellular
Ca2+ dysregulation with aging. Insulin regulation of glucose homeostasis is an
important modulator of neuronal plasticity. Also, maintenance of intracellular
Ca2+ homeostasis is vital for normal synaptic plasticity as well as cell excitability.
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1.10 Intracellular calcium levels
Calcium (Ca2+) is an essential ion that rules many aspects of cellular life,
including cellular excitability, exocytosis, apoptosis, toxicity, and transcription,
and mediates many cell functions, including muscle contraction, chemical sense,
cell proliferation, fertilization, immune response, learning and memory. For this
reason, intracellular Ca2+ levels are precisely regulated in young healthy
individuals. However, failure of this regulation occurs with aging and AD. The first
proposal of a “Ca2+ hypothesis of brain aging” by Khachaturian in 1984 provides
a simple cellular mechanism that alters Ca2+ homeostasis underlying many agerelated changes. After two more decades of studies, the relationship between
dysregulation of intracellular Ca2+ and pathological brain aging has become
clear and is now the key therapeutic target to treat many neurodegenerative
diseases.
Thanks to the excellent work of Sydney Ringer, who in 1883 discovered the
importance of Ca2+ signaling in the survival of fish, heart, and muscle
contraction. After 50 years, in the early 1940s, Lewis Victor Heilbrun confirmed
the theory that Ca2+ is a universal intracellular messenger able to regulate all
cellular reactions and that Ca2+ also involves neurotransmitter release into nerve
terminals [176, 177]. After several decades of research, it is clear that in the
brain, Ca2+ plays a critical role for synaptic activity, neuronal development,
neuronal survival, and cognition [178-180]. Discovery of patch clamping and
Ca2+ imaging techniques advanced our understanding of pathology associated
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with dysfunctions of Ca2+ signaling cascades [181]. At rest, intracellular Ca2+
concentration is very low (~100 nM free) and extracellular Ca2+ concentration (~
2 mM) is high, about a 20,000–fold concentration gradient. Intracellular [Ca2+] is
maintained within a specific limit by the different Ca2+ handling mechanisms
[182]. However, brain aging contributes to the loss of intracellular Ca2+
homeostasis [183, 184]. In healthy individuals, intracellular Ca2+ homeostasis is
tightly regulated and plays a vital role in neuronal survival and function. In
contrast, intracellular Ca2+ levels increase with aging, which contributes to
memory decline and other neurodegenerative disorders such as AD [180, 185,
186]. Specifically, an age-related increase in hippocampus Ca2+ levels has been
much investigated during the last several decades because Ca2+-dependent
after hyperpolarization is larger (AHP) in aged animals and links to cognitive
impairment with aging and AD [180, 182, 185-192]. In addition, high intracellular
Ca2+ levels and larger Ca2+ dependent AHP are seen in the hippocampus of
diabetic rats [193, 194].
It appears that the increase in hippocampal intracellular Ca2+ levels are mainly
mediated through voltage gated Ca2+ channels and N-methyl-D- aspartate
(NMDA) receptors on the plasma membrane, and intracellular Ca2+ release via
ryanodine receptors on the endoplasmic reticulum [195].
1.10.1 Voltage-gated Ca2+ channels
Voltage-gated Ca2+ channels (VGCCs) are found in the membrane of neurons,
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muscles, glial cells (excitable and non-excitable cells), and are permeable to
Ca2+ ions [196]. VGCCs are voltage-sensitive and mediate the fastest Ca2+
influx in response to membrane depolarization, thus, changing intracellular Ca2+
levels greatly within milliseconds [197-201]. As a result, Ca2+ enters the cell
through voltage-gated Ca2+ channels and serves as intracellular second
messengers to control a wide variety of cell functions. In cardiac, smooth, and
skeletal muscles, activation of VGCCs mediates contraction by increasing
intracellular Ca2+ levels and by further activating ryanodine dependent Ca2+induced Ca2+-release in the sarcoplasmic reticulum [202-206]. In the endocrine
cells, VGCCs activation influences the hormone secretion [207]. In the neurons,
Ca2+–mediated

process

via

VGCCs

include

synaptic

transmission,

neurotransmitter release, and gene transcription; it also activates calmodulindependent protein kinase ll (CaMKll) and protein kinase C (PKC) which are
important for neuronal survival, learning and memory [198, 208-217]. While Ca2+
channels serve as a key pathway for entry of Ca2+ into the neuron and initiate
many physiological events, inappropriate expression or dysfunction of VGCCs
can result is pathophysiological changes leading to neuronal Ca2+ dysregulation
and toxicity in the brain, which have been linked to neurodegenerative diseases
[218-221]. Furthermore, VGCCs density increases with aging, and this
contributes to cognitive decline with aging and AD [184, 222-224]. Therefore,
voltage-gated Ca2+ channels are important therapeutic targets for age-related
cognitive decline and other conditions.
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1.10.2 Structure and classification of voltage-gated Ca2+ channels
The five-polypeptide subunit that forms voltage-gated Ca2+ channels is a central
pore-forming α1 subunit, dimer of α2 and δ subunits and intracellular β subunit,
and transmembrane γ subunit. There are ten Cavα1 subunits that share four
homologous domains, each with six membrane-spain helices (S1-S6). S4
(Positively charged and hydrophobic) is the key controller for voltage-dependent
activation [197, 198, 208, 225-227] and P loop motif (negatively charged) is
located between S5 and S6. Together they form a pore that is permeable to
Ca2+ and barium [197, 228].

Figure 1.5 Voltage-gated Ca2+ channels structure.

High voltage activated (HVA) channels (P, Q, N, L, R-type) contain Caα1, Caβ,
Caγ, and Caα2δ subunits. Low voltage activated channels (T-type) contain
Caα1subunit modified from [220].
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The Caα1 subunit has three main families (Cav1, Cav2, Cav3) [226, 229]. The
Cav1 family includes four members (Cav1.1, Cav1.2, Cav1.3, Cav1.4) and all
four members encode neuronal L-type Ca2+ channels and Cav1.1 encodes
skeletal muscle Ca2+ channels [230-233]. Further, Cav1.1 knockout mice cannot
contract their diaphragms and die at birth [234]. Mice that lack Cav1.2 die in
utero because the heart muscle cannot contract [235]. Cav1.2 is also important
for neuronal function and mutations in this subunit links to bipolar disorder,
Schizophrenia, and depression [236-239]. Cav1.3 null mice are deaf due to loss
of Ca2+ current [240] and loss of normal auditory brain stem development [241].
Mice deficient in Cav1.4 are blind due to loss of normal function in the outer
retina [242, 243].
The Cav2 family has three members (Cav2.1, Cav2.2, Cav2.2) and gives rise to
P/Q-type [244], N-type, and R-type Ca2+ channels [233]. The Cav3 family has
three members (Cav3.1, Cav3.2, Cav3.3) that encode T-type channels [245].
Mice with a lack of Cav2.1, Cav3.1, and Cav3.2 display a range of dysfunctions
(seizures, slow heart rate, compromised coronary, epilepsies) [246-250].
The Cavβ subunit has four members (Cavβ1- Cavβ4) and links to Cavα1 domain
l-ll [251, 252]. The Cavα2δ subunit has four different members (Cavα2δ1−
Cavα2δ4)

and

is

anchored

to

extracellular

plasma

membrane

via

glycophosphatidylinositol (GPI) [253-255]. Earlier studies suggest that the
Cavα2δ subunit plays an important role in regulating synaptic targeting and
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release probability of voltage-gated Ca2+ channels in neurons [256, 257].
Table 2. Types of voltage gated Ca2+ channels (VGCCs) activation and
inactivation profiles modified from [258].
2+

Native current

α1-Subunit
subtypes

Activation
profile

Inactivation
profile

Ca dependent
inactivation

P/Q-type

α1A (CaV2.1)

High voltage

Moderate/slow

Yes/no

N-type

α1B (CaV2.2)

High voltage

Fast

Yes/no

High voltage

Moderate/slow

Yes

High voltage

Fast/moderate

No

Low voltage

Very fast

No

α1C (CaV1.2)
L-type

α1D (CaV1.3)
α1F (CaV1.4)
α1S (CaV1.1)

R-type

α1E (CaV2.3)
α1G (CaV3.1)

T-type

α1H (CaV3.2)
α1I (CaV3.3)

There are several members of the VGCCs in the brain due to different genes that
encode ten α1 subunits of Ca2+ channel, including L-type, N-type, P/Q-type, Rtype,

and

T-type

channels

[214,

259].

Based

on

physiological

and

pharmacological properties, they are categorized as high voltage (HVA) and low
voltage (LVA). HVA channels (L- type, P/Q-type, N-type) formed through a
combination of Cavα1, Cavβ, and Cavα2δ subunits activate in response to strong
and large depolarization. On the other hand, Low voltage-activated (T-type)
channels only contain the Cavα1 subunit and open in response to weak
depolarization [226, 260-263]. The R-type is intermediate voltage activated
channels. In neurons, both HVA and LVA channels can control neuronal firing
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properties [264-268].
1.10.3 Voltage-gated Ca2+ channels activation and inactivation
Activation of voltage-gated Ca2+ channels results in Ca2+ influx and mediates
neurotransmitter release, neuronal firing, hormone secretion, muscle contraction,
and gene expression. However, prolonged activation of Ca2+ channels
contributes to elevation of intracellular Ca2+ levels, which is cytotoxic [221].
Therefore, there are two types of Ca2+ channel inactivation, voltage- and/or
Ca2+-dependent inactivation, to limit intracellular Ca2+ overload. All voltagegated Ca2+ channels can be inactivated by voltage-dependent manner [269].
The underlying mechanism responsible for voltage-dependent Ca2+ channel
inactivation is different from voltage-gated K+ and Na+ channels (“ball and chain”
and “Hinged-lid”) mechanisms [270].

Many studies suggest that prolonged

depolarization triggers structural changes in four S6 of the α1 subunits, and
further exposes docking site for the domain l-ll linker. Thus, it modulates
inactivation of voltage-gated Ca2+ channels [269, 271-273]. Other subunits of
Ca2+ channels also influence the kinetics and rate of inactivation.
Voltage-gated Ca2+ channels inactivate not only in response to voltage, but also
to the influx of Ca2+ [274]. Ca2+-dependent inactivation becomes important
when studying the effects of drugs on Ca2+ channel currents. A rise in
intracellular Ca2+ triggers binding of Ca2+ to the channel and initiates
inactivation [275] and Calmodulin plays a vital role in Ca2+-dependent
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inactivation [276]. Therefore, barium was used as a charge carrier when
obtaining Ca2+ channel currents while studying insulin effects on VGCCs.
1.10.4 Ryanodine receptors
Ryanodine receptors (RyRs), intracellular Ca2+ release channels, are located in
the endoplasmic (ER) reticulum membrane [136, 277], and mediate rapid
intracellular Ca2+ release into the cytosol, which allows the amplification of
intracellular Ca2+ concentration. RyRs are widely expressed in almost all tissues
(muscle, myocardium, and neurons) and are involved in a variety of key Ca2+
signaling events [278], ranging from excitation-contraction coupling in muscle
cells to learning and memory in nerve cells. There are three major RyRs isoforms
(RyR1-3) and they are named after plant alkaloid ryanodine [279]. Ryanodine is a
natural agonist at low concentration, which allows efflux of Ca2+ from ER and
increases intracellular Ca2+ levels. At high concentrations (~20 uM), Ryanodine
is an antagonist, which inhibits the Ca2+ flow out of the ER.
RyRs are the largest ion channels and the highest-conductance intracellular
Ca2+ channel, with a molecular mass that is greater than megadalton [280].
RyRs are regulated by the Ca2+ ion and VGCCs [281]. Ca2+ influx through
voltage-gated Ca2+ channels triggers second messenger signals that open the
RyRs channels and give rise to large Ca2+ release from internal Ca2+ stores
(endoplasmic reticulum) [282, 283]. Thus, Ca2+ activation of the RyRs on the
endoplasmic reticulum amplifies the intracellular [Ca2+] through Ca2+-induce
Ca2+-release (CICR) process [284]. Additionally, various ions, small molecules,
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and proteins may also regulate the RyRs function, including protein kinase A
(PKA), FK506 binding proteins, and calmodulin (CaM) [285-287]. In skeletal and
cardiac muscle, RyR1 and RyR2 play a critical role in excitation and contraction
coupling [288, 289]. High intracellular Ca2+ concentration induces muscle
contraction and Ca2+ ATPase dependent Ca2+ uptake by sarcoplasmic
reticulum results in relaxation [281, 290]. In neurons, RyRs are crucial for signal
transduction and influence hormone secretion, synaptic plasticity, and learning
[291-293].

Figure 1.6 Ryanodine receptors and cognitive function with aging

Ryanodine receptors (RYRs) on the endoplasmic reticulum (ER) undergo
functional changes with aging. Furthermore, the RYRs mediated increase in
Ca2+-induced Ca2+-release (CICR) is one of the major sources of Ca2+
dysregulation with aging. Moreover, amplified CICR influences the size of AHP
and cognitive function. As a result, dysfunction of RYRs leads to an increase in
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intracellular Ca2+ via CICR, which further contributes to larger AHP, Ca2+
dysregulation, and memory decline.

1.10.5 Ryanodine receptor isoforms and expression
Ryanodine receptor isoforms are RyR1, RyR2, and RyR3 and are expressed in
various tissues. RyR1 is the most intensely studied type and its main function is
to trigger Ca2+ efflux from the sarcoplasmic reticulum membrane of skeletal
muscle. RyR1 is highly expressed in the skeletal muscle [294, 295]. Also, it is
widely distributed in cardiac muscle, smooth muscle, stomach, kidney, thymus,
cerebellum, purkinje cells, adrenal glands, ovaries, testis, and B-lymphocytes at
low levels [294, 296-299]. Dysfunction of the RyR1 gene is associated with lifethreatening muscle diseases such as malignant hyperthermia [300] and
multiminicore disease [301].
RyR2 is dominantly expressed in the cardiac muscles [277]. Different
concentrations of RyR2 are also detected in purkinje cells of the cerebellum,
cerebral cortex, stomach, kidney, adrenal glands, ovaries, thymus, and lungs
[302-305]. Mutation in the RyR2 gene may cause arrhythmogenic right
ventricular dysplasia type 2 and Ventricular arrhythmias by changing Ca2+
homeostasis [306-308].
RyR3 is present in the brain and mainly found in the hypothalamus, corpus
striatum, and hippocampal neurons [296, 304, 309]. Different studies suggest
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that inappropriate expression or dysfunction of RyR3 links to Alzheimer’s disease
[136, 186].

1.10.6 Structure of ryanodine receptors
All three isoforms (RyR1, RyR2, RyR3) share similar structure. The structure of
RyR1 (Skeletal muscle ryanodine receptors) is widely studied and it includes four
identical subunits and is divided into two regions: a transmembrane (TM) region
and a cytoplasmic (CY) region [294, 295]. The CY region plays a critical role in
regulating RyR1 channel gating properties via interacting with intracellular
messengers. Dysregulation of the CY region of RyR1changes its gating and links
to many diseases [310].
RyR2 is dominantly expressed in the heart and brain and is activated by Ca2+
influx

through

plasma

voltage-gated

Ca2+

channels

in

response

to

depolarization. Peng et al. used electron microscopy to map the structure of open
and closed states of RyR2 from porcine hearts. The results suggest that RyR2
has different cytoplasmic domain compare to RyR1 due to rotation of the central
domain, which influence the RyR2 channel gating [311].

1.11 Hippocampus
Hippocampus is critical for learning and memory [312] and is highly vulnerable
to damage and loss during aging and AD [111, 191, 313-315]. The
hippocampus, located in the medial temporal lobe, belongs to the limbic family,
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one on each side of the brain. The human hippocampus has a curved shape
resembling a seahorse; it appears as a ‘C’ shape in hippocampal cultured
neurons. In addition to the hippocampus, the cerebellum, amygdala, and other
systems are also involved in learning and memory.
The hippocampus is responsible for the formation and consolidation of shortterm memory and long-term memory, as well as spatial navigation. The H.M
study is the starting point for understanding the importance of the hippocampus
in memory. H.M is a famous patient whose case provided an understanding of
how our brain works. After the neurosurgeon removed H.M’s hippocampus,
patient was unable to form new memories, and, as a result, he forgot daily
events as fast as they occurred [316]. The H.M case study continued for five
decades until his death, and the study results shed light on the relationship
between cognitive and neuronal organization of memory [317]. Since H.M
became

amnesic

after

bilateral

hippocampus

lesion,

the

removal

of

hippocampus is responsible for his memory impairment; moreover, magnetic
resonance imaging study further confirmed that lesion of the hippocampus can
result in global and enduring amnesia [318]. This study, along with cumulative
animal studies, made it clear that the hippocampus plays a critical role in the
formation of immediate memory, long-term memory, and memory retention [319].
In addition, earlier studies suggest that the hippocampus volume decreased with
aging [320]. Furthermore, in neurodegenerative diseases such as Alzheimer’s
disease, the hippocampus is one of the first brain regions to become damaged.
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Also, an increase in hippocampal neurogenesis is one of the hallmarks of early
AD [321, 322].
On the other hand, in healthy individuals, high levels of insulin receptors have
been seen in CA1, a hippocampal region that is important in learning and
memory [159, 323]. The interruption of insulin production and insulin receptor
activity may cause cognitive decline [28]. Also, neuron loss in the CA1 region of
the hippocampus differentiates the healthy individual from AD patients [313, 324326]. Therefore, losing and/or damaging the hippocampal neurons causes
significant cognitive problems.

1.12 Insulin actions on neurons
Insulin has wide raging effects in neurons of various brain regions, including
regulating neuronal activity and synaptic function. Insulin and insulin receptors
are present in the fetal central and peripheral nervous system, where it
promotes axonal growth and brain development in the hippocampal cultured
neurons [327]. Insulin can be produced and released from the hippocampal
cultured neurons in response to depolarization [125, 126]. Insulin inhibits
norepinephrine uptake by the hippocampal cultured neurons [328]. In the
hypothalamus, insulin reduces the activity of POMC, AgRP, and steroidogenic
factor 1 (SF-1) neurons through KATP channel activation [329, 330]. In the
hippocampus, insulin increases insertion of NMDA receptors into the cell
membrane [89] via tyrosine phosphorylation of NR2A and NR2B subunits [85].
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Thus, insulin may promote long-term potentiation, which is important for learning
and memory. Insulin-dependent internalization of the AMPA receptor [88, 331,
332] is important for long-term depression, which is another important
mechanism for consolidation of navigational memory in the hippocampus. Insulin
also regulates inhibitory synapse by increasing cell surface GABAA receptor
expression [91, 92, 333]. In addition, insulin enhances synaptic plasticity by
increasing the expression of dendritic postsynaptic density scaffolding protein
(PSD-95), which is important for the formation of the postsynaptic junction [334]
and Ca2+ homeostasis in hippocampal neurons (Maimaiti et al., 2017). Insulin
stimulates the translocation of glucose transporter-4 (Glut-4) to hippocampal
plasma membranes [100]. Glut-4 is important for glucose uptake and utilization
in the brain. As a result, insulin regulates neuronal metabolism and energy
needed for learning and memory via Glut-4. In addition, insulin also regulates
visual system function by controlling synapse density [84]. Insulin modulates Ltype Ca2+ current and intracellular Ca2+ levels in rod photoreceptors [335].

1.13 Thesis significance
Hippocampus-dependent memory loss is one of the hallmarks of brain aging and
Alzheimer’s disease (AD). This growing epidemic includes an estimated 5.3
million people in the United States, with the economic burden on healthcare
estimated at 259 billion dollars (http://www.alz.org/facts/). Most importantly, the
day-to-day lives of those affected by AD and their families must be considered
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as we investigate new therapeutic targets and new approaches for the
treatment of this devastating disease. Indeed, AD therapeutic options are very
limited in their ability to improve the lives of those impacted by this disease.
Therefore, innovative and effective therapeutic strategies are necessary to
address the needs of this patient population.
In recent years, the study of insulin as a cognitive enhancer has gained
momentum. Insulin and its receptors have been detected in the hippocampus,
one of the major brain regions that is damaged and/or lost in Alzheimer’s
disease [155, 336]. In addition, insulin regulates energy for proper brain function
and survival [158], and insulin signaling has been shown to be deficient in
postmortem brain tissue of AD patients [337, 338]. Thus, increasing insulin
signaling in the brain appears to be a valid therapeutic target for improving
cognitive function in aging and/or AD. Earlier clinical trials have shown that
intranasal insulin treatment significantly improves memory in AD patients [3135] .Therefore, based on these clinical studies as well as animal studies,
intranasal insulin administration appears to be one of the best methods to treat
cognitive decline due to its minimal effect on systemic glucose levels and noted
improvements in memory processes. However, there have been only a few
studies focusing on identifying the neuronal molecular mechanisms underlying
these effects. My dissertation is designed to identify the potential mechanisms
responsible for insulin-mediated memory improvement as those seen in human
and animal studies. Specifically, I focus on identifying whether insulin can offset
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cognitive decline with aging through a mechanism dependent on reestablishing
Ca2+ homeostasis.
Intracellular Ca2+ signaling may be a key neuronal molecular regulator of
hippocampal-dependent memory. Intracellular Ca2+ levels increase associates
with memory decline in aging and AD [156, 314, 339, 340]. Thus, we examined
the relationship between insulin, memory and intracellular Ca2+ levels to better
understand the mechanism(s) underlying insulin action on hippocampal
neurons. This information will enable to us to better understand how insulin
therapy may affect patients and may also shine light on the underlying neuronal
mechanisms.
The following manuscript has been published in the Journals of Gerontology:
Series A: J Gerontology A Bio Sci Med Sci. 2016 Jan;71(1):30-9. Epub 2015
Feb 6. As an initial step, we explored the role of intranasal insulin in improving
hippocampal-dependent memory in experimental aged animals. Additionally, we
delineated insulin’s effects on Ca2+-dependent after hyperpolarization in the
CA1 region of the dorsal hippocampus using hippocampal slices recordings in
young and aged rats. Because brain aging is the greatest risk factor for AD,
studies into how insulin may alter biomarkers of brain aging could improve
current therapeutic strategies for memory loss with aging and AD.
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Chapter 2 Intranasal insulin improves age-related cognitive deficits and
reverses electrophysiological correlates of brain aging
Authors: Shaniya Maimaiti, Katie L Anderson, Chris DeMoll, Lawrence L Brewer, Ben
Rauh, Chris J Gant, Erick Blalock, Nada M. Porter, Olivier Thibault

Synopsis
Peripheral insulin resistance is a key component of metabolic syndrome
associated with obesity, dyslipidemia, hypertension, and Type 2 diabetes. While
the impact of insulin resistance is well recognized in the periphery, it is also
becoming apparent in the brain. Recent studies suggest that insulin resistance
may be a factor in brain aging and Alzheimer’s disease (AD) whereby intranasal
insulin therapy, which delivers insulin to the brain, improves cognition and
memory in AD patients. Here, we tested a clinically-relevant delivery method to
determine the impact of two forms of insulin, short-acting insulin lispro
(Humalog®) or long-acting insulin detemir (Levemir®), on cognitive functions in
aged F344 rats. We also explored insulin effects on the Ca2+-dependent
hippocampal

afterhyperpolarization

(AHP),

a

well-characterized

neurophysiological marker of aging which is increased in the aged, memory
impaired animal. Low-dose intranasal insulin improved memory recall in aged
animals such that their performance was similar to that seen in younger animals.
Further, because ex vivo insulin also reduced the AHP, our results suggest that
the AHP may be a novel cellular target of insulin in the brain, and improved
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cognitive performance following intranasal insulin therapy may be the result of
insulin actions on the AHP.

2.1 Introduction
Results from preclinical settings argue that peripheral insulin resistance, a
component of type 2 diabetes and/ or the metabolic syndrome, may have a
negative impact on cognitive function. Emerging studies report that in diabetic
models, insulin responses are attenuated in the brain, possibly indicating the
presence of insulin resistance in this tissue. Clinical and preclinical studies show
that insulin and insulin-like growth factor-1 (IGF-1) receptors, their message and
their function, are often reduced in the hippocampus during normal and
pathological aging [27, 111, 124, 150, 341]. Similarly, in animal models of aging
and Alzheimer’s disease (AD), brain insulin receptor signaling is reduced, often in
the presence of peripheral metabolic dysregulation [28, 342-348]. Importantly,
several studies provide evidence that brain insulin therapy can greatly reduce
cognitive decline with age and/ or AD, and even improve memory in young adults
[reviewed in 33].

In recent studies examining the effects of insulin on cognition, insulin has been
administered via the intranasal route to bypass the blood brain barrier. Notable,
Born and colleagues have shown that intranasal insulin is capable of entering the
human brain rapidly [349]. However, the underlying mechanism(s) leading to
cognitive improvement are not yet clear. Potential molecular/ cellular targets
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affected by insulin in the brain and capable of offsetting cognitive decline include
changes in neuronal firing [350], Ca2+-dependent K+ channels [351], GABA
currents [352] and tau and Aβ metabolism [353-355]. Insulin also alters synaptic
structures [356, 357], modifies synaptic plasticity [88, 358, 359] and increases
delivery of NMDA receptors to the plasma membrane [89]. Similar effects have
been observed in response to IGF-1 replacement, showing increased AMPAmediated excitatory postsynaptic potentials [360, 361], and increased NMDA
receptor trafficking [362], effects that appear capable of offsetting age-dependent
cognitive decline [363]. Further, MRI data in men and women has provided
evidence that intranasal insulin can have an impact on brain blood flow [364],
and on whole-body insulin sensitivity via regulation of hypothalamic activity [365,
366]. Whether this later effect is purely mediated by central insulin effects or
reflects permeation of small insulin amounts into the bloodstream is currently
being investigated [367-369].

Another important candidate mechanism that may underlie the effects of
intranasal insulin pertains to Ca2+ homeostasis. Ca2+ dysregulation is prominent
in models of diabetes [370]. In the dorsal root ganglion and the hippocampus of
animals with STZ-induced diabetes [193, 371], broader Ca2+ action potentials,
larger Ca2+-dependent afterhyperpolarizations (AHPs), and aberrant intracellular
Ca2+ release are seen [193, 372, 373]. Impaired memory and long-term
potentiation maintenance is also present [374]. Clinical data also supports a role
for Ca2+ dysregulation in peripheral insulin resistance as evidenced by the
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presence

of

abnormal

and

sustained

adipocyte

Ca2+

elevations

in

hyperinsulinemic, obese subjects [375]. Similar evidence for an increase in Ca2+
levels in skin fibroblasts from Type 2 diabetics has also been reported [376]. In
recent work, we have shown that the Ca2+-dependent AHP, which increases in
amplitude and duration with aging [377-379], is sensitive to insulin (ex vivo), and
that this sensitivity is reduced by a high fat diet [380].

While some studies in humans demonstrate the efficacy of intranasal insulin as a
cognitive enhancer, studies in animal models are required to understand the
potential mechanisms underlying the beneficial effects of intranasal insulin.
However, only one prior study has measured the impact of intranasal insulin on
brain function in the awake animal, focusing on olfactory discrimination in the
young mouse [381]. Because the greatest risk factor for AD is aging, research
into how central nervous system insulin signaling affects brain aging may
improve understanding of the biological conditions. Further, because of the
sustained growth in the aging population, implementing strategies to reduce the
impact of brain aging will likely benefit the aging population, and by extension,
may reduce the incidence of age-related neurodegenerative diseases that share
cellular mechanisms with brain aging (e.g., AD).

We, therefore, assessed learning and memory performance in aged rats in
response to two different insulin formulations (short-acting insulin Humalog® and
long-acting insulin Levemir®), and quantified Ca2+ homeostasis. Insulin is
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available primarily in shorter- and longer-acting forms, and intranasal longeracting insulin formulations (e.g., Levemir®) may potentially be superior to
shorter-acting ones (e.g., Humalog®) especially in APOE-ε4 carriers [382]. In
addition, because insulin is often formulated with zinc, to more specifically
address the impact of insulin, we studied a zinc-free insulin formulation (Apidra®
), as well as zinc alone on the AHP. Overall, our goals were to test whether
intranasal insulin could reduce cognitive decline in aged animals, as well as
redress

the

accompanying

neuronal

Ca2+

dysregulation

seen

in

the

hippocampus of aged animals.

2.2 Methods
Animals: Young male F344 (3 months old), aged male F344 (21 months old),
and young male Sprague-Dawley rats (2-6 months old) were used for this study.
Young F344 animals were not treated with insulin, and were used to help gauge
the impact of intranasal insulin on memory function in aged F344. All animals
were fed an 18% protein rodent diet (Harlan Teklad, diet #2018; Madison, WI).

In vivo insulin delivery and doses: Levemir® doses were approximately
0.0715, 0.143, or 0.286 IU/day/rat delivered in two 5 uL applications applied to
the tip of the right naris using a P10 Eppendorf pipette (see supplemental figure
1) [adapted from 383]. Humalog® dose was chosen to deliver 0.0715 IU/day/rat
for behavioral characterization. An intranasal 0.286 IU/rat dose was also
administered once to aged animals (n = 3) to monitor the impact on peripheral
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glucose (supplemental Table 1). Each application was separated by 1 min,
during which the animal was held supine and immobile in a DecapiCone®
(Braintree Scientific Inc., Braintree, MA). Each animal was acclimated to this
procedure for 4 days prior to initiation of the Morris water maze protocol. All
animal groups were exposed to the DecapiCone® for the same duration, and no
signs of stress from the bagging procedure were noted. The insulin doses were
chosen to approximate several clinically-relevant doses used in past studies
ranging from 10 IU/day to 40 IU/day and were adjusted by brain weights.
Assuming a 70 year old human brain weighs 1360 g [384], 10, 20 and 40 IU/day
are equivalent to 0.0074, 0.0147, and 0.0294 IU/day/g of brain, respectively.
Assuming a 21 month old F344 brain weighs 2.06 g [385], our equivalent doses
were 0.035, 0.069 and 0.138 IU/day/g of brain. It should be noted that these
values may underestimate final insulin concentration given the greater olfactory
epithelium surface in the nasal passages of the rat (50%), compared to man (8%)
[386]. Insulin solutions were made fresh weekly from 100 U/mL vials (Humalog®,
insulin lispro, Lilly; Levemir®, insulin detemir, Novo Nordisk) and diluted into
sterile 0.9% saline.

Blood glucose levels: To ensure that the intranasal delivery did not result in
reduced peripheral glucose levels, and to test whether stress from the acute
restraint procedures (DecapiCone®) could elevate blood glucose levels, we
measured blood glucose (FreeStyle Lite glucometer; Abbott Laboratories, Abbott
Park, IL) from dorsal tail veins in a subset of aged animals either exposed with
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intranasal Levemir® (n = 5 from each treatment group) or Humalog® (n = 3),
both before and approximately 1 hour after dosing (see supplemental Table 1).

Animal behavior treatment groups and Morris water maze (MWM)
procedures: Two cohorts of F344 animals were used for behavioral
characterization (supplemental Fig. 1B). One cohort of animals (n = 50) was used
to test the impact of long-acting insulin Levemir® at 3 different doses (low,
medium and high; n = 10 per group) compared to an intranasal saline young
group (3 months; n = 10) and an intranasal saline aged group (21 months old; n
= 10). A second cohort of aged animals (n = 20) was used to test the impact of
short-acting insulin Humalog® against saline (n = 10 per group). For analysis,
behavioral data from the two aged saline control groups in both cohorts were
combined because memory performance on probe day was similar (path length
to goal, p = 0.89 and cumulative search error, p = 0.913). One aged animal in the
saline group died during acclimation prior to initiation of behavioral testing. The
remaining 69 animals where trained on the MWM. Animals were considered
visually impaired or unable to learn the task if they could not find the platform on
all 3 of the trials on the cue day (visual platform) and at least one of the
remaining 3 training days. Based on these conditions, 2 aged Humalog® animals
and 3 aged low-dose Levemir® animals were removed from the analysis.
Behavioral results are therefore presented on 64 animals, 10 young saline, 19
aged saline, 8 aged low-dose Humalog® (10 IU/day), 7 aged low-dose Levemir®
(10 IU/day), 10 aged medium-dose Levemir® (20 IU/day), and 10 aged high42

dose Levemir® (40 IU/day). On cue day, no significant differences were found
across any of the groups on measures of path length (1-way ANOVA, p>0.05)
and swim speed across insulin dose (1-way ANOVA, post-hoc p>0.05), indicating
motivation and motor activity were likely similar.

Insulin or saline treatment in both cohorts was initiated 4 days prior to the
initiation of training (sup. Fig. 1B) and was delivered 1-3 hours before testing on
the MWM. The MWM protocol has been published elsewhere [380, 387], but
briefly, water temperature was maintained at 26-27oC, and black liquid tempera
paint was used to make the water opaque and hide the submerged escape
platform (~1.5 cm below water surface). A Videomex-V acquisition system and
water maze analysis software (version 4.64, Columbus Instruments, Columbus,
OH, USA) were used to track and measure animal movements. Animals were
allowed 60 s to find the platform, after which they were guided to it. Each animal
stayed on the platform for 30 s before returning to a heated holding chamber for
about 2 min. On cue day, a white cup hanging above the partially submerged
platform helped orient the animals. Animals were subjected to 3 trials per day
(semi-random drop location for each trial) for cue and training days. Twenty-four
hours after the last training day, a probe trial was initiated with the platform
removed (60 s max swim time). Swim speed was derived from the distance
travelled over time on the last trial of the third training day and on the first trial of
the cue day. On all cue and training days the inter-trial interval was
approximately 150 s. All behavioral experiments were conducted with the
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experimenters blind to the treatment groups using color coding of the insulin and
saline vials.

Electrophysiology:

Hippocampal

slices

were

used

across

two

electrophysiological setups, one monitoring extracellular field potentials and, the
other measuring intracellular potentials (e.g., AHP). All data were acquired using
pClamp 8.0 (Molecular Devices MDS, Toronto, Canada) through a Digidata
1320A A/D converter (Molecular Devices). Potentials (e.g., amplitude and
duration of AHPs, field EPSPs) were quantified off-line using Clampfit (Molecular
Devices). Nineteen of the twenty behaviorally characterized aged animals
(second cohort used to test the impact of short-acting insulin Humalog® against
saline) were used 2-5 weeks after the last day of behavioral characterization to
determine the impact of single intranasal insulin dose in vivo. From those, a total
of 30 slices used for extracellular field potential recordings (Fig. 2D and 2E) and
13 cells used for intracellular recordings (Fig. 2B and 2C) were used for statistical
analyses and are presented using an n of 1 per cell/slice. In data presented in
figure 3, 16 Sprague-Dawley animals (2-6 months old) were used to monitor the
impact of zinc and Humalog® ex-vivo both extracellularly and intracellularly (30
slices and 23 cells, respectively). Work presented in figure 4 (intracellular
physiology only) is compiled from a total of 17 F344 male rats split into young (n
= 8; 3 months) and aged (n = 9; 22 months). This last group of animals yielded
recordings from 6 cells for young ACSF, 8 cells from young Apidra®, 6 cells for
aged ACSF and 5 cells for aged Apidra®.
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Figure 2.1 Morris water maze spatial learning and memory task.
(A) Path length to submerged goal platform on the initial 3 days of training
showed improved performance across all groups tested (RM ANOVA p<0.0001),
however, no group effect was seen. On probe day, with platform removed,
animals receiving low doses of insulin (Humalog® or Levemir®) showed reduced
path lengths to goal (B) and improved memory performance based on reductions
in cumulative search error (C). Analysis of swim speed measured on the third
training day shows aged F344 animals are slower (note no effect of insulin dose
on speed (D)). Means ± SEM are shown.

Asterisks indicate significant

differences from the young saline group at p<0.05; pound sign indicates a trend
(p=0.059) in comparison to the young saline group.
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Figure 2.2 Impact of in vivo intranasal Humalog® on intracellular and
extracellular physiology.

(A) Representative intracellular recording of the AHP following a series of 4
action potentials (truncated to emphasize the AHP). The mAHP (B) and sAHP
(C) amplitudes recorded 3-7 hours after intranasal Humalog® in F344 rats were
not significantly different. EPSP amplitudes (D) and I/O slopes (E) when recorded
extracellularly 3-7 hours after intranasal Humalog® also were not significantly
altered. Means ± SEM are shown.
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Figure 2.3 Impact of ex vivo Humalog® and zinc on the AHP.
(A) Representative voltage trace of the AHP recorded in a cell from an ACSF
treated slice (black) and a Humalog® treated slice (1 nM, grey). Data are derived
from young Sprague-Dawley animals. Traces are truncated to emphasize the
AHP. Significant reductions in the sAHP amplitude (C) and duration (D) were
seen in response to Humalog® as well as zinc. Note that zinc and low
concentration Humalog® seem to work more robustly on the sAHP (only a trend
was noted for the mAHP (B)). No significant effect was detected during
extracellular recording of field EPSP amplitudes (E) or slopes of the I/O curve
(F). Means ± SEM are shown.
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Figure 2.4 Zinc-free Apidra® reduces the AHP ex vivo.

The mAHP amplitude is shown in (A) and the sAHP amplitude is shown in (B).
Means ± SEM are presented in response to 1nM Apidra®. These data are taken
from young and aged F344 rats. Asterisks indicate significant age-dependent
increases in the mAHP and sAHP, and pound signs illustrate significant insulinmediated reductions in the AHP. Again, the impact of insulin seems more robust
on the sAHP compared to the mAHP. These recordings were obtained with 4.5
mM glucose in the ACSF.
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Figure 2.5 Intranasal insulin delivery and experimental timeline.

(A) This photograph shows a supine aged F344 rat during intranasal insulin
delivery. The animal is held in place temporarily in a decapicone® with the head
gently restrained. Note that the pipette tip is not inserted into the naris but
presented at the entrance of the right naris. (B) Timeline used for behavioral
(Morris water maze – MWM) and electrophysiological characterization presented
in figures 1 and 2 using two cohorts of F344 rats. T1, T2 and T3 are initial
training days on the MWM and are followed with a 24 h memory recall task
(Probe). Each red triangle represents a consecutive day for intranasal insulin
delivery in 2 different cohorts of animals. All animals were treated/ handled
similarly across cohorts, and received 11 saline or insulin doses. Animals in
cohort 2 were also used 2-5 weeks after behavioral characterization, to test the
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electrophysiological impact of intranasal Humalog® in vivo. Electrophysiology
data presented in figures 3 and 4 are derived from Spraque-Dawley and F344
animals, respectively.

Table 3. Blood glucose analysis.

(n=5)

10 IU
Levemir®
(n=5)

20 IU
Levemir®
(n=5)

40 IU
Levemir®
(n=5)

40 IU
Humalog®
(n=3)

Pre-Dose

73.2 ± 2.9

72.6 ± 6.2

70.8 ± 7.2

75.2 ± 3.8

65.3 ± 2.0

Post-Dose

82.0 ± 3.7

82.2 ± 4.0

74.2 ± 6.5

78.4 ± 5.3

82.3 ± 6.0

Saline

Numbers represent mean ± SEM peripheral glucose levels (mg/dL) taken before
(Pre-Dose) and 30-90 min after intranasal insulin Levemir® or Humalog®
delivery (Post-Dose). The number in parentheses represents the number of aged
animal tested in each group. Intranasal insulin (Levemir® or Humalog®) did not
reduce peripheral blood glucose levels.
Field potentials: Rats were anesthetized with Isoflurane® prior to decapitation.
Brains were quickly removed and placed in oxygenated artificial cerebro-spinal
fluid (ACSF) of the following composition (in mM): 114 NaCl, 3 KCl, 10 Glucose,
1.25 KH2PO4, 26 NaHCO3, 8 MgCl2, 0.1 CaCl2. Hippocampi were sectioned
(coronal) with a Vibratome® 3000 (Bannockburn, IL) set at 400 µm. Slices were
transferred to an interface-type recording chamber (static) containing oxygenated
recording ACSF of the following composition (in mM): 114 NaCl, 3 KCl, 10
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Glucose, 1.25 KH2PO4, 26 NaHCO3, 2.5 CaCl2 and 1.3 MgCl2. The recording
chamber was kept at 32° C and warm moist 95 % O2/ 5 % CO2 was continually
delivered to the chamber. Bipolar synaptic stimulation was delivered through a
SD9K stimulator (Astro Med Inc., Grass Instr., Warwick, RI). Input/output curves
(I/O) were recorded using a series of increasing voltage steps. The relationship
between stimulus intensity and EPSP amplitudes (prior to dendritic spike
contamination) was fit (linear, r2>0.9) to yield a measure on the slope of the I/O.
Data are also reported as the absolute amplitudes of the EPSPs measured as
the maximum deflection from baseline. Insulin (1, 100, 500 nM Humalog®)
and/or zinc treatment (130 nM – see AHP-intracellular recordings) under these
conditions was initiated 1 hour after placing the slices in the chamber
(compounds remained in the chamber for the duration of the experiment.

AHP-Intracellular recordings: Hippocampal slices (350 µm) were transferred
from the static chamber and placed in a perfusion chamber (RC22C, Warner
Instruments, Co., Hamden, CT) and maintained in a continuous flow of
oxygenated ACSF pre-heated at 32°C using a TC2Bip/HPRE2 in-line heating
system (Cell Micro Controls, Northfolk, VA). The ACSF contained 2 mM CaCl2
and 2 mM MgCl2 and in some experiments (Figure 4 only), the traditional 10 mM
glucose concentration was replaced with 4.5 mM glucose. This was done to test
whether higher glucose concentrations altered insulin sensitivity. We chose 4.5
mM to help maintain tissue health and physiology for extended hours [388], to
approximate values in anesthetized preparations [389], and to consider
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fluctuations in brain glucose levels across a day [390]. As previously described,
cells were impaled with sharp microelectrodes filled with 2M KMeSO4 and 10mM
HEPES, pH 7.4 (tip resistance 90-120 MΩ) [377]. Recordings of membrane input
resistance (IR) were obtained in response to 800 ms, 200 pA hyperpolarizing
current injections using an Axoclamp 2B amplifier (Molecular Devices, MDS,
Toronto, Canada) while holding the cell at -70 mV. To generate an
afterhyperpolarization (AHP) cells were held at -65 mV (baseline) and
depolarized with a 100 ms current injection to generate four Na+ action
potentials.

The

medium

AHP

(mAHP)

was

measured

as

the

peak

hyperpolarization immediately after the offset of the depolarizing current injection,
the slow AHP (sAHP) was measured 800 ms after the end of the current
injection. The AHP duration was measured from the end of the depolarizing step
until return to baseline.

Several concentrations and formulations of insulin were tested ex vivo by
addition

to

the

solution

bathing

the

hippocampal

slices.

Humalog®

concentrations of 1, 100, and 500 nM were used. A zinc (ZnCl2) concentration of
130 nM was used to mirror levels of free zinc attained in 250 nM Humalog®.
Apidra® (insulin glulisine, Sanofi, a zinc-free insulin formulation) was used at 1
nM and results were compared to ACSF. Under these experiments, Apidra® was
used to treat slices both in the static chamber and during recording of the AHP.
Apidra® was continuously perfused into the flow of the oxygenated recording
ACSF using a precision perfusion pump (Orion Research, Model 341B, Boston,
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MA) and resulting in a final concentration of 1 nM (diluted in sterile saline once a
week from the 600 uM stock). Only neurons with input resistance > 25 MΩ,
holding current < 500 pA and action potentials reaching above zero mV were
included in the analysis.

Statistics: Statistical analyses testing for significance (p<0.05) of main factors
and interactions used a 1-way or a 2-way ANOVA as well as a t-test design
(some electrophysiology). Fisher’s PLSD was used for post-hoc comparisons. All
tests were conducted using StatView statistical package (version 5, Cary, NC) or
GraphPad Prism

V5

(San

Diego, CA).

Together the

behavioral and

electrophysiological data presented here are derived from a total of 106 animals.

2.3 Results
Blood analyses. Several studies show that intranasal insulin either has no
effect, or a moderate lowering effect (within the euglycemic range) on peripheral
blood glucose [31, 367-369, 383, 391, 392]. A 2-way RM ANOVA shows
intranasal insulin did not alter peripheral blood glucose levels in a subset of the
aged animals (n = 5/group) 30-90 min after intranasal insulin Levemir® delivery
(supplemental Table 1). In another group of aged animals, 40 IU Humalog® also
was unable to alter blood glucose levels. This result is consistent with transport
of insulin to the perivascular space around blood vessels, indicating the hormone
may not have crossed into the blood stream [34, 386].
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Behavioral analyses. All groups learned to find the platform in the MWM as
demonstrated by a significant decrease in path length to goal across the first 3
days of training (F(2,116)=27.2; p<0.0001). During this learning phase, path length
(Fig. 1A) however, showed no significant differences across groups with age or
intranasal insulin dose (2-way RM ANOVA). As shown previously [387, 393],
analysis of swim speed revealed a significant group effect (F(5,58)=12.5;
p<0.0001) with post-hoc tests indicating aged animals swam at slower speeds
compared to young animals, but no difference between the insulin treatment
groups was noted (Fig. 1D). Latency to target, as predicted from slower speeds
in aged animals, was significant across 3 days of training (F(2,116)=28.9;
p<0.0001), with increased latency seen in all aged animals compared to young
saline animals (data not shown). Because of this decrease in swim speed we
chose to assess search errors and quantify memory performance on the probe
day (no platform) using a proximity measure analysis. This approach is less
dependent on swim speed than latency and is tabulated using a cumulative
search error derived from the subject’s distance to the platform summed over the
time to reach the platform and is then subtracted from an ideal path (straight
line); smaller values are indicative of better performance [394].

Compared to the learning component of the task, the 24 h memory recall
component measured during the probe trial (1-way ANOVA) revealed a
significant group effect on path length to goal (F(5,58)=2.9; p<0.05) and on
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cumulative search error (F(5,58)=3.3; p<0.05). Post-hoc analyses identified a
significant increase on path length and cumulative search error in the aged saline
(p<0.05) and aged medium-dose Levemir® (p<0.005) groups compared to the
young saline group (Figs. 1B and 1C). A trend (p=0.059) for improved
performance was found for the high-dose Levemir® animals on path length
measures only. Notably, no significant differences were found between young
saline treated and aged animals treated with either low-dose Humalog® or lowdose Levemir® on path length or cumulative proximal distance (Figs. 1B and
1C), indicating that the lower dose intranasal insulin significantly reduced agedependent memory loss. Additional post-hoc analyses on memory performance
in aged animals, comparing combined low dose insulins (Humalog® and
Levemir®) with combined medium- and high-dose Levemir®, revealed significant
improvement in the low-dose insulin group on path length (F(1,33)=5.25; p<0.05)
and cumulative search error (F(1,33)=5.91; p<0.05). Thus, each of the different
insulin formulations (Humalog® and Levemir® at low-doses) improved
performance despite being administered to two separate cohorts of aged
animals, indicating reproducibility of the insulin effect, and it appears lower,
rather than higher doses of insulin are able to redress cognitive decline with
aging.

Electrophysiology analyses. Based on improved memory recall observed in
aged animals treated with low-dose insulins, we next characterized the effects of
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in vivo intranasal insulin on hippocampal electrophysiology in a subset of the
Humalog® treated animals that were behaviorally characterized. Supplemental
Table 2 shows that passive membrane properties were not different between
groups and suggests cells with comparable baseline characteristics were
analyzed. Intracellular recording of CA1 pyramidal neurons were obtained from
animals

treated

with

intranasal

saline

or

Humalog®

(see

Methods).

Approximately 3-7 hours following intranasal insulin delivery the Ca2+-dependent
AHP was not significantly different between groups (Figs. 2B and 2C; t-test). This
was true for measures of AHP amplitude (medium and slow AHP) and duration
(not shown). Extracellular synaptic potentials also showed no significant
difference across groups (Figs. 2D and 2E; t-test). EPSP amplitudes measured
at 33% of the I/O were slightly larger in the Humalog® treated animals and I/O
slopes based on EPSP amplitude measures were somewhat reduced (Figs. 2D
and 2E, respectively, p<0.1). These results are surprising given our prior report
that insulin application to hippocampal slices reduces the AHP [380]. In the prior
study, however, hippocampal slices were perfused for 15 minutes with insulin
and then studied electrophysiologically. The results obtained in the present study
raise the possibility that the delay between intranasal insulin exposure and
electrophysiological recording (3-7 h) was too long and that the effect of insulin
on the AHP may have dissipated. Thus, to confirm that insulin must be present in
order to alter hippocampal physiology, we tested a range of ex-vivo insulin
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concentrations and formulations on hippocampal slices from a separate group of
animals.

We used young animals in the next series of experiments, and examined three
different doses of Humalog®, comparing Humalog®’s actions to zinc and ACSF.
In most insulin formulations, zinc is used to promote hexamer formation and
prolong stability and duration of action in vivo. However, zinc is also known to
modify ion flux across neuronal membranes, reducing activity at NMDA and
GABAA receptors, ion channels associated with memory-related processes
[reviewed in 395]. Extracellular recordings in the presence of zinc or Humalog®
showed that neither EPSP amplitudes, nor I/O slopes were significantly altered
when compared to ACSF controls (Figs. 3E and 3F; 1-way ANOVA). Similarly to
data shown in figure 3, these results indicate little if any, effects of insulin on
extracellular postsynaptic potentials.

Intracellular recordings obtained from the same group of animals showed that the
Ca2+-dependent AHP was sensitive to treatment with zinc or insulin. As
previously reported, measures of postsynaptic excitability demonstrated the
sensitivity of the AHP to both zinc [396] and insulin [380]. A main effect of
treatment on the slow AHP (F(4,18)=3.34; p<0.05) and its duration (F(4,18)= 4.49;
p<0.02) was seen across 5 groups of recorded cells (Figs. 3C and 3D). Albeit
being somewhat reduced, the mAHP was not significantly altered by insulin (Fig.
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3B). These results suggest a component of the insulin effect on the AHP could
well be mediated by zinc found in this insulin formulation. To test the direct
impact of ex vivo insulin on the AHP, we next investigated a zinc-free formulation
of insulin (Apidra®).

In this next series of experiments we obtained hippocampal slices from young
(n=8) and aged (n=9) F344 rats and focused exclusively on intracellular
potentials and the response to ex vivo Apidra® exposure (1 nM). Further, a
recent study identified that 0.1-100 nM exogenous insulin concentrations could
reliably elicit dose-dependent activation of the insulin signaling pathway in human
brain tissues [20], and approximated physiological levels near 1 nM. For these
reasons, we used 1 nM Apidra®. As previously reported [377-379, 397] and
shown here (Fig. 4), mAHP and sAHP amplitudes recorded in CA1 pyramidal
neurons were increased (F(1,24)=17.6, p<0.0005; F(1,24)=4.7, p<0.05, respectively)
in aged, compared to young animals (2-way ANOVA). Treatment with the zincfree Apidra® insulin significantly reduced the AHP in slices from both young and
aged rats as indicated by a main effect of treatment on the mAHP (F(1,24)=32,
P<0.0001) and the sAHP (F(1,24)=29.1, p<0.0001). However, the Apidra® mediated AHP reduction was larger in aged animals compared to young animals
(Figs. 4A and 4B) as evidenced by a significant interaction term in the 2-way
ANOVA (F(1,24)=10.9, p<0.005 for the mAHP). These results are consistent with
our prior work using Humalog® showing that the hippocampal AHP is sensitive to
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insulin [380]. In the experiments presented here however, it is clear that insulin
alone has a direct effect on the AHP, and that this effect persists even when
lower, more physiological glucose levels are used in the ACSF (experiments in
Figure 4 were conducted with 4.5 rather than the typical 10 mM glucose
concentration - see Methods). Finally, it is interesting to note that Apidra® did not
alter holding current when compared to control cells (sup. Table 2), indicating
insulin is neither activating nor inhibiting a tonic current near resting potential.

2.4 Discussion
Studies in humans have shown that intranasal insulin has promising cognition
enhancing effects, alleviating, and perhaps even slowing the progression of agerelated neurodegenerative disorders. However, the mechanisms underlying
insulin’s effects in the brain are unclear. In order to identify potential
mechanisms, we treated aged rodents with intranasal insulin, attempting to
model aspects of the clinical trials reporting on the beneficial impact of intranasal
insulin. Here, we describe physiological actions of insulin in the brain, highlighting
a potential new mechanism of action of insulin on hippocampal function in both
young and aged rats. This first analysis of intranasal insulin in aged animals
demonstrates that intranasal insulin improved memory recall in aged F344 rats.
We show that the effect on memory was observed in two separate cohorts of
animals, using two different insulin formulations (Humalog® and Levemir®)
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delivered at relatively low dose (0.0715 IU/day/rat). Thus, these studies also
demonstrate reproducibility of the effect of insulin on behavior. We also show that
the Ca2+-dependent afterhyperpolarization (AHP), and in particular the slow
AHP, a Ca2+-related biomarker of brain aging which increases with age and
cognitive decline, is reduced by acute insulin exposure in aged animals and
could well represent a novel target of brain insulin underlying the improvement
seen in memory recall.

Long-acting insulin (Levemir®) was as effective as short-acting insulin
(Humalog®) on memory recall in aged animals, inducing levels of performance
indistinguishable from those seen in young animals. Levemir®’s long duration of
action is dependent on the presence of albumin in the periphery and a fatty acid
modification of the insulin structure, increasing its’ affinity for albumin.
Humalog®’s shorter duration and faster onset are due to amino acid
modifications in the β-chain of the insulin molecule. Because both versions of
insulin were able to reverse cognitive decline to a similar degree in aged animals,
our results suggest both insulins were able to gain access to the brain following
intranasal administration despite structural differences. While results from clinical
studies in memory-impaired older adults have reported improved word recall
within 15 min post intranasal delivery [398], a prior clinical study on younger
adults demonstrated the superiority of a faster acting insulin (Novolog®)
compared to regular insulin (Actrapid®) on delayed word recall after 7 weeks of
intranasal 160 IU/day Novolog® [392]. Using shorter delays (i.e., 10 min) a
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recent study reveals 40 IU intranasal insulin delivery to young adult males
improves odor-cued spatial memory [399]. Clearly, the memory enhancing
effects of insulin are depend on treatment regimen (acute vs. subchronic), but
also on the age and gender of the subject [400], as well as on the insulin
formulation used [382, 401]. As mentioned above, a single, acute intranasal dose
of

insulin

is

capable

of

enhancing

memory

in

humans

and

our

electrophysiological studies showing an acute action of insulin on the AHP
indicate that insulin can have rapid effects on neuronal processes critical to
memory (see below). However, in the current study, it is unclear whether the
effects on cognition observed here were due to an acute action of insulin (i.e., the
dose received 1-3 h prior to memory testing), or the result of the cumulative daily
treatments received over the course of 8-11 days.

he decrease in the AHP by insulin was observed in field CA1 of the
hippocampus, a synaptic zone which plays a key role in memory processing.
Decreasing the AHP in this structure would be expected to increase neuronal
excitability and facilitate throughput during physiological activation. Consistent
with this, exogenous insulin increases excitatory neurotransmitter receptor
trafficking including NMDA and AMPA receptors [88, 358, 359, 402], thus
promoting network activation. Furthermore, pure insulin has been shown to
activate an inward current and depolarize hypothalamic neurons via activation of
transient receptor potential channels, providing supporting evidence that insulin
raises excitability [403]. However, recent results provide evidence that insulin or
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other therapies that raise insulin (exendin-4 and glucagon-like peptide-1),
increase functional GABAA conductances in CA1 [352] as well as in CA3
pyramidal neurons [404]. This observation is in line with prior reports of
enhanced GABAA function in response to insulin, a resulting decrease in synaptic
activity [350, 351] and a long-lasting enhancement of inhibitory post-synaptic
currents (IPSCs) [405]. The net result, therefore, of enhancing both steady-state
hyperpolarizing (GABA-mediated) and short term depolarizing forces (e.g.,
reduced AHP or direct depolarization) could well increase synaptic signal-tonoise, thereby improving throughput and neuronal communication. Clearly, as
seen in hypothalamic arcuate nucleus neurons, it is important to note that
insulin’s modulatory influence on membrane potential/ excitability, is insulin
formulation dependent, as well as cell-type specific [403].

To extend slice health and allow for extended neuronal recordings, high glucose
concentrations (10 mM) are commonly used in the ex-vivo hippocampal slice.
However, this superphysiological glucose concentration may alter insulin
sensitivity in the brain. For this reason, we used lower glucose levels in some
experiments while maintaining tissue health (see Table 2), and more closely
approximating physiological glucose

levels.

Importantly,

significant

AHP

reduction was seen irrespective of recording conditions (10 or 4.5 mM glucose).
Thus, the results presented here appear compatible with potential effects of
insulin on hippocampal neurons in vivo.

64

The placebo group in almost all clinical trials studying the impact of intranasal
insulin on memory function is generally exposed to either saline or HOE-31, a
dilution buffer that does not contain zinc. Given that all insulin formulations
except Apidra® contain zinc, our results showing that Apidra® is capable of
reducing the AHP in hippocampal neurons ex vivo could have clinical
significance. These data are consistent with insulin per se being able to alter
hippocampal physiology, and suggest that insulin and not zinc may be
responsible for the CNS effects of intranasal insulin on memory. Clearly further
clinical trials with Apidra® appear warranted.
Because the AHP is dependent on a Ca2+-activated K+ conductance, the insulinmediated reductions in the AHP may be due to inhibition of Ca2+ influx [406] or
inhibition of L-type Ca2+ channel currents as seen in pinealocytes [407]. Taken
together, these results suggest insulin acts through the insulin receptor to reduce
Ca2+-mediated functions possibly through PI3 kinase- or tyrosine kinasemediated phosphorylation of Ca2+ channel proteins. Indeed, insulin can enhance
mitochondrial function and therefore, Ca2+ homeostasis through PI3 kinase
mechanisms in the periphery [193]. Insulin also increases sarco-endoplasmic
reticulum Ca2+-ATPase (SERCA) function in heart cells via an Akt (protein
kinase B) pathway, and in neurons, insulin has been shown to reduce KV1.3
potassium channel function [408]. Notably, all of these potential mechanisms are
consistent with reductions in available Ca2+, and hence, reductions in the
amplitude of Ca2+-dependent hyperpolarizing potentials.
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Our data cannot address whether the beneficial actions of intranasal insulin on
memory recall are mediated, in parts or in whole, by the effects of insulin on the
AHP. While suggestive that this may be the case, we do not provide evidence to
support this conclusion. Further, because young animals were not tested for the
impact of intranasal insulin, future studies will be needed to test the hypothesis
that the observed effect is age-selective, or generally nootropic. Finally, although
a similar insulin dose yielded quantitatively similar enhancement on memory
recall in two cohorts of aged animals, it is not clear that higher Humalog® doses
might also be ineffective, similarly to higher Levemir® doses.

The present results shed new light on a previously unrecognized insulin
mechanism in the brain. Reductions in the AHP could enhance neuronal
communication and might represent a pathway through which low dose
Humalog® or Levemir® improve memory recall in aged animals. We show that
insulin targeted the AHP, a Ca2+-mediated conductance, and reduced AHP
amplitude and duration, elevations of which are characteristic of brain aging. We
propose that facilitating insulin signaling restores Ca2+ homeostasis in aged
animals, resulting in optimal levels of membrane excitability and synaptic
plasticity, in part by limiting the amplitude and duration of the AHP in CA1
neurons (Figs. 4 and 5). During aging, reductions in brain insulin levels and/or
insulin receptor function (see Introduction) may help promote neuronal Ca2+
dysregulation, resulting in impaired membrane excitability and reduced synaptic
plasticity (e.g., larger AHP). Clearly, given the reductions in insulin receptor RNA
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and protein in the aged rodent [27, 111], greater occupation of the leftover insulin
receptors with insulin could well offset reductions in signaling through these
receptors, or may even slow the age-related reduction in insulin receptor density.
Collectively, these results indicate robust associations between brain insulin,
Ca2+ homeostasis, and aging-related cognitive decline, and suggest the value of
further developing “insulin-raising” strategies for treating cognitive decline in age
and disease, perhaps curbing the development of AD.
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Chapter 3 Link between studies

3.1 Intranasal insulin and cognition
In the late1990s, several clinical studies suggested that diabetes is a risk factor
for cognitive decline and AD [142, 409, 410]. Also, through population-based
studies, it has become clear that dysregulation in insulin signaling increases the
risk for cognitive decline with aging and AD [139, 411-417]. In addition, imaging
studies have shown that diabetes patients have smaller hippocampi and that
brain functional connectivity also changed compared to healthy individuals [418422]. Furthermore, studies have found that insulin receptors are widely
expressed in different regions of the brain and play a vital role in regulating
whole-body glucose metabolism, energy balance, and neurotransmission in the
brain [423]. In addition, aging can alter insulin and insulin receptor function,
reduce pancreatic beta cells function, and reduce insulin secretion by pancreatic
beta cells [424, 425]. These studies ignited interest in the effects of insulin in
the brain in the context of cognition and led the way for later research
confirming that insulin is an important cognitive enhancer.
Interest in the study of intranasal insulin has also stemmed from a number of
clinical studies demonstrating that intravenous insulin infusion during clamped
glucose conditions improved memory [15, 29, 137, 149]. Clearly, due to the
danger of hypoglycemia, insulin infusion peripherally is not a feasible approach
for treating AD. On the other hand, it has been shown that intranasal insulin
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delivery targets the brain, bypassing the blood brain barrier, and without the risk
of hypoglycemia [349, 426]. There are several ongoing intranasal insulin clinical
trials, including study of nasal insulin to fight forgetfulness (SNIFF), intranasal
insulin in children and young adults at risk of type 1 diabetes, intranasal insulin
for the HAND (HIV-associated neurocognitive disorder), and intranasal insulin
for stroke patients. My research is focus on the neuronal effects of intranasal
insulin on the context of cognitive decline with aging.
Intranasal administration of insulin appears to be one of the best methods to
treat cognitive decline due to its minimal effect on systemic glucose levels and
its acute improvements on hippocampal-dependent memory. Intranasal insulin
enters the brain mainly through olfactory and trigeminal pathways [427-429].
Insulin binds to insulin receptors in various brain regions, including the
hippocampus [430]. The hippocampus is well-known as a principle brain region
for learning and memory. Normal insulin signaling of neurons within the
hippocampus area is typically associated with healthy brain aging. Furthermore,
deficiency in brain insulin signaling accelerates pathological brain aging and
cognitive decline. The goal of intranasal insulin study in our lab is to achieve a
greater understanding of the effects of insulin and insulin signaling pathways
that might slow or reverse age-related memory decline and pathologies.
We found that a repeated low dose of intranasal insulin had a positive effect on
memory recall in aged F344 rats. However, medium and high doses of insulin
did not have a beneficial effect on memory in aged F344 rats. This varying
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outcome is in line with clinical intranasal insulin studies. Clinical studies show
that intranasal insulin therapy improves memory maintainability in healthy and
AD patients [32, 431]. Although intranasal insulin enhances memory in AD
patients, varying outcomes arise from its clinical setting usage [431]. Men and
women with AD respond differently to intranasal insulin dosages [36]. In
addition, some clinical studies have reported that patients carrying at least one
copy of the Apolipoprotein E4 (the strongest genetic risk factor for late onset
Alzheimer’s disease) did not benefit from intranasal insulin treatment [37].
Hence, these clinical trials revealed that not everybody responds equally to
intranasal insulin therapy. Based on both clinical and animal studies, different
formulations and dosages of insulin, as well as gender and ApoE status in AD
patients increase the outcome variability in intranasal insulin treatment. A clear
understanding of the mechanisms underlying insulin actions in the brain will
help address these varying outcomes and increase the efficacy and safety of
using intranasal insulin to treat cognitive impairment.

3.2 Insulin and Ca2+-dependent after hyperpolarization
It is also well documented that the Ca2+-dependent AHP (Ca2+ related
biomarker of brain aging) increases in aged and memory-impaired animals. The
greater AHP is correlated with reduced neuronal excitability and learning ability
[30, 184, 377, 379, 380, 432-437]. It is widely accepted that reducing the AHP is
one viable pathway to enhance learning and memory in aging animals. Data
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from our lab suggests that insulin reduces the AHP in CA1 neurons from young
and aged rat hippocampal slices [30, 380]. These findings are in line with
previous behavioral studies, suggesting that insulin therapy improves memory
by reducing the Ca2+ dependent AHP [30]. However, the molecular
mechanism(s) that result in such an interaction has not been studied in depth.
Ca2+ and potassium are the main ions that influence the amplitude and duration
of AHP. Here, I focused on the relationship between insulin and intracellular
Ca2+ homeostasis.
Another factor besides insulin that is related to cognitive decline in aging and AD
is elevated intracellular Ca2+ concentration [187-191]. The two main sources of
intracellular Ca2+ are Ca2+ influx via voltage-gated Ca2+ channels (VGCCs) on
the plasma membrane and Ca2+ efflux via ryanodine receptors (RyRs) mediated
Ca2+-induced Ca2+-release (CICR) on the endoplasmic reticulum.

3.3 Voltage-gated Ca2+ channels dysfunction with aging
Voltage-gated Ca2+ channels (VGCCs) are responsible for Ca2+ influx into the
cytosol in response to membrane depolarization. VGCCs play a critical role in
neuronal excitability, neurotransmission and Ca2+ signaling, which is important
for learning and memory in healthy and disease states. All types of VGCCs are
expressed in the hippocampus and involved in neuronal firing, action potential,
and synaptic plasticity [438]. Furthermore, the density of plasma membrane
VGCCs increases with aging and results in elevated intracellular Ca2+ levels,
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which is toxic to neurons and leads to cell death [226, 439-441]. Earlier studies
showed that elevated Ca2+ influx via VGCCs contribute to bigger AHP and
cognitive decline in aged animals [184, 224, 437, 442, 444-446]. In addition,
voltage-gated Ca2+ channel blockers have been shown to improve cognition in
aged animals, as well as in dementia and AD patients [447-450]. Moreover,
knockout of voltage-gated Ca2+ channels have a great impact on memory in
aged animals [451, 452]. In hippocampal neurons, Ca2+ entry though VGCCs
during

membrane

potential

triggers

Ca2+-induced

Ca2+-release

from

endoplasmic reticulum via the ryanodine receptors, causing amplification of
intracellular Ca2+ levels [220, 377, 435, 453].

3.4 Ryanodine receptors dysregulation with aging
Ryanodine receptors (RyRs), an intracellular Ca2+ release channel, is
responsible for Ca2+ release from endoplasmic reticulum (ER) and triggers
amplification of intracellular Ca2+ levels through RyR-medicate Ca2+-induced
Ca2+-release (CICR). RyRs plays a vital role in maintaining intracellular Ca2+
homeostasis. Thus, RyR-mediated Ca2+ release is critical to cellular
physiological events ranging from muscle contraction to learning and memory. All
RyRs isoforms (RyR1-3) are expressed in the various regions of the brain,
including the hippocampus, cerebellum, olfactory region and cerebral cortex,
which are located within the presynaptic terminals of neurons. The RyRs
channels have been found to show changes in functional efficacy during
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aging/AD [136, 377, 435, 453-458] and influence the amplitude and duration of
Ca2+ dependent afterhyperpolarization (AHP) [192, 377]. Additionally, increases
in RyRs-mediated intracellular Ca2+ release through CICR mechanisms during
aging results in loss of intracellular Ca2+ homeostasis, thus greatly influencing
cognitive function [192, 377, 459].
Taken together, age-related increases in RyRs-mediated intracellular Ca2+
release mechanisms are also responsible for larger AHP seen in memory
impaired aged animals. Ultimately, lowering Ca2+ efflux via RyRs is important for
reducing the AHP.

However, a central question of whether insulin reduces VGCCs currents
remains unanswered. Furthermore, it is not clear whether insulin affects RyRs
function. To address these questions, the activity of VGCCs was recorded from
neurons that were treated with acute (10 minute) insulin vs. control solutions. In
parallel studies, Ca2+ imaging was used in cultured hippocampal neurons to
evaluate the RyRs-dependent intracellular Ca2+ level changes in insulin treated
neurons. Our approach helped us to delineate one of the many neuronal
molecular mechanisms underlying insulin’s effect on memory through the
reduction of AHP via regulating intracellular Ca2+.

The following manuscript has been submitted to Neuroscience.
In this manuscript, I continue to study the underlying mechanisms responsible
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for the memory enhancing effects of intranasal insulin in aged animals. It is
clear that Ca2+-dependent AHP is one of insulin’s neuronal targets from the
previous study presented in this dissertation (Chapter 2). Those data led me to
focus further on the relationships between insulin and hippocampal intracellular
Ca2+, which influence the amplitude and duration of AHP. Voltage-gated Ca2+
channels and ryanodine receptors are major factors that contribute to
dysregulation of intracellular Ca2+ homeostasis present in aged animals.
Hence, I tested acute insulin’s effect on single live hippocampal neurons in
culture using whole-cell patch clamping. In addition, insulin effects on resting
and depolarization mediated intracellular Ca2+ transients were examined in the
single live neurons using Ca2+ imaging techniques.
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Chapter 4 Novel Ca2+-related targets of insulin in hippocampal neurons
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Synopsis
Both insulin signaling disruption and Ca2+ dysregulation are closely related to
memory loss during aging and increase the vulnerability to Alzheimer’s disease
(AD). In hippocampal neurons, aging-related changes in Ca2+ regulatory
pathways have been shown to lead to higher intracellular Ca2+ levels and an
increase in the Ca2+-dependent afterhyperpolarization (AHP), which is
associated with cognitive decline. Recent studies suggest that insulin reduces
the Ca2+-dependent AHP. Given the sensitivity of neurons to insulin and
evidence that brain insulin levels are reduced with age, insulin-mediated
alterations in Ca2+ homeostasis may underlie the beneficial actions of insulin in
the brain. Indeed, increasing insulin signaling in the brain via intranasal delivery
has yielded promising results such as improving memory in both clinical and
animal studies. However, while several mechanisms have been proposed, few
have focused on regulation on intracellular Ca2+. In the present study, we further
examined the effects of acute insulin on Ca2+ pathways in primary hippocampal
neurons in culture. Using the whole-cell patch-clamp technique, we found that
acute insulin delivery reduced voltage-gated Ca2+ currents. Fura-2 imaging was
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used to also address acute insulin effects on spontaneous and depolarizationmediated Ca2+ transients. Results indicated that insulin reduced Ca2+ transients,
which appears to have involved a reduction in ryanodine receptor function.
Together, these results indicate insulin regulates pathways to control intracellular
Ca2+ which may be responsible for reducing the AHP and improving memory.
This may be one mechanism contributing to improved memory recall in response
to intranasal insulin therapy in the clinic.

Keywords: diabetes, intranasal, excitability, imaging, electrophysiology, aging
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4.1 Introduction
Aging is a major risk factor for Alzheimer’s disease (AD), and both brain aging
and AD are characterized by a progressive decline in cognitive and memory
function. A promising treatment for cognitive impairment seen in AD is to
maintain or enhance insulin signaling in the brain. Insulin is a cognitive and
neural modulator that is synthesized by pancreatic β-cells and enters the brain
through the blood brain barrier [460-463]. In the periphery and in the brain,
insulin has been shown to bind to insulin receptors and to regulate glucose
uptake by inducing translocation of glucose transporters to the plasma
membrane [464]. In aging or AD, declining insulin levels, insulin receptor
numbers, and/or glucose transporters can lead to dysregulation in glucose
uptake. This is evidenced by nearly two decades of research showing strong
associations between diabetes, cognitive decline, and AD [16, 141-144]. At the
cellular level, brain insulin deficiency and reduction in insulin signaling, perhaps
mediated by insulin resistance, could represent one of the altered pathways
linked to altered memory function or synaptic communication during aging and
AD [15-20, 30]. Underlying this relationship is evidence that insulin receptor
numbers and their functions are decreased in aging and AD animal models [111,
346, 465, 466]. As such, interruption of insulin production or in insulin receptor
activity may cause cognitive decline [323]. One approach designed to combat
this reduction in insulin signaling that has received much interest in the clinic is
the use of intranasal insulin delivery to selectively increase ligand concentration
in the brain [349].
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Intranasal insulin therapy has been shown to improve memory function in AD
patients [32, 431]. The intranasal route of insulin administration raises insulin
acutely in the central nervous system without much risk of peripheral
hypoglycemia [30, 367, 426, 467, 468]. Importantly, it significantly enhances
memory in both healthy individuals and AD patients [31, 33-35, 37]. In aging and
AD animal models, the positive impact of intranasal insulin in combating cognitive
decline has also been reported [30, 381, 467, 469-473]. The mechanisms of
action in the brain, and specifically on neurons of the hippocampus where insulin
plays a recognizable role in learning and memory [28, 111], remain however,
largely unknown.
Because previous work on mechanisms of cognitive aging has focused on Ca2+
dysregulation in hippocampal neurons providing evidence of enhanced Ca2+
levels [377, 439, 445, 474-476] and voltage-gated Ca2+ channels (VGCC)
activity [224, 432, 445, 477], we focused on studying two well-characterized
Ca2+ sources in hippocampal neurons in culture. The rationale for this approach
was based on recent evidence from our lab that insulin acutely reduces the
Ca2+-dependent afterhyperpolarization (AHP) in neurons recorded from
hippocampal slices [30, 380]. The AHP is a hyperpolarization potential that is
enhanced in aging, limits neuronal firing, and is associated with cognitive decline
[379, 380, 433, 478]. The larger AHP seen in aging is mediated in part by an
increase in the density of L-type voltage gated Ca2+ channels (L-VGCC) [224]
and by Ca2+-induced Ca2+-release (CICR) through activation of RyRs [377,
479, 480]. Together, these two sources of Ca2+ contribute to elevated
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intracellular Ca2+ levels, larger AHPs and altered synaptic communication.
Thus, here, we tested the hypothesis that acute insulin (glulisine, zinc-free and
fast acting) could reduce Ca2+ levels, or stabilize Ca2+ homeostasis by altering
VGCC function and/ or ryanodine receptor (RyR) function. To address these
questions, we used patch clamp recording of VGCCs with rapid drug delivery,
as well as Fura-2 imaging during depolarization in the presence or absence of
RyR blocker. Our results indicate that insulin is able to reduce Ca2+ levels
during periods of neuronal depolarization and that this is mediated, at least in
part, by reductions in VGCC and RyR function. These two aging-sensitive
neuronal Ca2+ targets are therefore also sensitive to the actions of insulin and
could represent novel therapeutic targets for cognitive decline in aging and/ or
AD. Re-establishing Ca2+ homeostasis represents a mechanism by which
insulin and by extension, intranasal insulin, may offset learning and memory
dysregulation in vivo.

4.2 Experimental procedures
Cell culture: Hippocampal mixed (neuron/glia) cultures were prepared as
described previously [439, 481, 482] and established from (E18) SpragueDawley rats. E18 pups and hippocampi were dissected under a microscope in
ice-cold Hank’s balanced salt solution (Thermo Fisher Scientific Inc., MA, USA)
supplemented with 4.2 mM NaHCO3, 10 mg/L gentamicin and 12 mM HEPES
(pH 7.3). Hippocampi were transferred to a 37oC 0.25 % Trypsin EDTA solution
79

(Thermo Fisher) and left at room temperature for 11 minutes. Trypsin was
removed and the hippocampi were washed three times with Minimum Essential
Medium (MEM). Hippocampi were then titrated, and diluted with MEM to the
desired final concentration (5-7 x 105 neurons/ml) before being plated onto 35
mm poly-L-lysine coated dishes. Cultured neurons were incubated (36°C, 5%
CO2, 95% O2) for 24 h before the first medium exchange. At this time, half of the
medium was replaced with 90% SMEM supplemented with 10% Horse serum.
After three days in vitro (DIV), half of the medium was replaced with SMEM,
horse serum, 5-Fluoro-2-Dioxyuridine and uridine to stop glial cell growth. At DIV
10, a sodium bicarbonate solution (200 uL) was added to help maintain pH and
limit evaporation.
For whole-cell recording experiments, plastic culture dishes were used (Corning
Inc., Corning, NY, USA) and for Ca2+ imaging experiments, glass bottom culture
dishes (Mattek Crop., Ashland MA, USA) were used. All data presented were
collected between DIV 13 and 17, and experiments were conducted following a
24 h exposure to lower glucose-containing MEM (5.5 mM; MEM with no added
glucose). This was done to maintain normal glucose oxidation rates and insulin
sensitivity [482]. All data presented were obtained at room temperature.
VGCC recording solution: For whole-cell, external recording solution of VGCC
currents, was as follows (in mM): 111 NaCl, 5 BaCl.H2O, 5 CsCl, 2 MgCl2, 10
glucose, 10 HEPES, 20 TEA.Cl.H2O, pH 7.35 with NaOH, and 500 nM
tetrodotoxin (TTX) was added before recording to inhibit Na+ channels. The
internal pipette solution (in mM): 145 CH4O3S-methanesulfonic acid, 10 HEPES,
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3 MgCl2, 11 EGTA, 1 CaCl2, 13 TEA.Cl.H2O, 14 phosphocreatine Tris-salt, 4
Tris-ATP, 0.3 Tris-GTP, pH 7.3 with CsOH. All solutions were sterile filtered.
Drugs and solution application: External solutions were delivered using a rapid
solution exchange system (SF77A - Warner Instruments Corp. Hamden, CT,
USA) positioned approximately 400 um above the cell being recorded. Flow rate
was set to 0.3 mL/min and a control solution supplemented with TTX was used to
establish baseline recording (~10 min) during which passive cell membrane
properties were obtained (e.g., membrane resistance, capacitance, access
resistance), and currents were allowed to run up. Rapidly switching the position
of the tubing delivering the solutions above the recorded or imaged cell allowed
us to tightly control the environment and deliver either insulin, KCl (50 mM),
ryanodine (20 uM), a high-affinity small peptide interacting with insulin (affibody,
ab31906, Abcam, Cambridge, MA, USA; 100 ng/mL, 500 ng/mL, or 1 ug/mL), or
an insulin receptor antibody (S961, Phoenix Pharmaceuticals Inc., Burlingame,
CA., USA; 500 ng/mL). Insulin glulisine (10 nM, a fast acting, zinc-free insulin)
was prepared weekly in external recording solution from a 6 uM stock (Apidra®
600 uM, Sanofi-Avantis US. LLC, diluted in sterile saline). This concentration was
chosen based on our previous results from our lab [30, 380].
Whole-cell recording and analysis: To minimize capacitance artifacts, whole-cell
patch-clamp electrodes were coated with polystyrene Q-dope before recording
(see Table 1 for membrane and electrode properties). The culture dish was
rinsed with external solution twice and then supplemented with TTX. To allow for
currents to stabilize, all data were recorded 5-10 min after the whole-cell
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configuration was achieved. Current/voltage (I-V) relationships (-60 to + 30 mV)
were used to identify the voltage step eliciting the maximal current amplitude.
This voltage was used for each cell in the study in order to compare data at the
peak of the I-V relationship (150 ms depolarization). Cells were either held at -70
mV (150 ms) or -40 mV (350 ms) and currents were elicited at the maximal peak
response. All currents were leak subtracted using 5-8 scaled hyperpolarizing
sub-pulses. Because insulin may alter cell size, we report on measures of current
densities (pA/pF), derived from dividing peak current amplitude by membrane
capacitance (measured in pClamp) for each cell. All recordings were conducted
on the stage of an epifluorescence microscope (E600FN - Nikon Inc., Melville,
NY, USA) placed on an anti-vibration table. An amplifier (Axopatch 1D Molecular Devices, Sunnyvale, CA, USA) in combination with an A/D board
(Digidata 1200 - Molecular Devices) and acquisition software (pClamp 7 Molecular Devices) were used for electrophysiology acquisition. Data were
digitized at 5-10 KHz and low-pass filtered at 2-5 KHz and were quantified in
Clampfit 7 (Molecular Devices).
Ca2+ imaging and analysis: Cultures were incubated in Ca2+ imaging solution
(in mM): 145 NaCl, 2.5 KCl, 10 HEPES, 10 D-glucose, 2 CaCl2, 1MgCl2, 0.01
glycine, pH 7.3 with NaOH for 30 min in the dark. This solution contained 2 uM
Fura-2 AM (F1221 – Invitrogen) and was made monthly with fresh DMSO
(0.085%) and Pluronic® F-127 (0.015%, weight/ volume). Each culture dish was
then rinsed three times with Ca2+ imaging solution containing no indicator and
placed in the dark for 20 min (de-esterification period). The dish was then placed
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on the stage of the microscope. Intracellular Ca2+ transients were visualized by
exciting Fura-2 at 340 +/-20 nm and 380 +/- 20 nm using a high-speed filter
changer (Lambda DG4, Sutter instruments, Novato, CA, USA) to obtain a
ratiometric value independent of indicator concentration. Emitted light was
passed through a dichroic filter (400 nm high pass) and an emitter filter (520 +/30 nm; Chroma Technology) and was digitized onto the sensor of an EMCCD
camera (iXon-Andor Technology, Belfast, Ireland). Ca2+ transients were
measured and analyzed using Imaging Workbench 5.0 (INDEC BioSystems
Santa Clara, CA) as previously published [481, 482]. The greater ratio (340/ 380
nm) values reported reflect higher Ca2+ levels. The gray value for both excitation
wavelengths of each cell measured (region-of-interest - ROI drawn around soma)
was background subtracted from an area devoid of cellular components. When
imaging Ca2+ during periods of depolarization (50 mM KCl), the Ca2+ imaging
solution was modified with a reduction in NaCl to 97 mM in order to control for
osmolarity changes.
Statistics: Data were analyzed using Prism 5.0 (GraphPad Software, La Jolla,
CA, USA). Paired t-tests and repeated measures ANOVA were used to test for
group differences with significance set at p< 0.05. For electrophysiology
experiments, data from each recorded cell (perfusion conditions precluded
recording 2 cells per dish) was considered a single data point (i.e., n=1). For
Ca2+ imaging data, 5-10 cells in the field of view were averaged and considered
a single data point (i.e., n=1).
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4.3 Results
4.3.1 Effect of insulin on whole-cell Ca2+currents.
Ca2+ currents were recorded before and after a 10 mins perfusion of either
external solution (time control; n=19), or external solution supplemented with 10
nM insulin (n=17) using the SF77A fast perfusion system. Cells were held at -70
mV and were stepped to the peak voltage determined from the I-V relationship.
Peak and late currents (obtained immediately prior to termination of the voltage
step) were quantified and are presented normalized to cell size (pA/pF). A
significant decrease in peak (-20%; p<0.0001) and late (-31%, p<0.002) Ca2+
currents in response to acute insulin application was seen (Figure 1A-C). Based
on a subset of the cells recorded (n=7 per group), there was no change in the I-V
relationship (Figure 1D).
To determine if the actions of insulin were selective for L-type Ca2+ channels,
cells were held at -40 mV and stepped (350 ms) to peak voltage. Whole-cell
recording analysis indicated that similarly to reductions seen from a holding
potential of -70 mV, L-type-enriched Ca2+ currents were significantly reduced
(Figure 1E and F) both at the peak (-22%; p<0.0004) and during the late current
phase (-33%; p<0.005). The data suggest that insulin did not alter the inactivation
rate of currents (Figure 1A), and did not show a greater inhibitory effect on
currents elicited from -40 mV. This indicates insulin does not selectively reduce
L-VGCCs but instead, may reduce all VGCCs.
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Figure 4.1 Ca2+ channel currents are reduced in response to acute insulin
application in mixed hippocampal cultured neurons.
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A. Example of VGCC currents recorded during recording solution perfusion
(black) and after 10 min insulin (grey) during maximal step depolarization from 70 mV. B.-C. Quantification across groups of cells following 10 min of insulin
perfusion (Insulin) versus recording solution perfusion (Time Control) shows peak
and late Ca2+ currents were significantly reduced (p<0.05). D. In a subgroup of
cells, current-voltage relationships were not significantly altered. E. Example of
the effects of insulin on L-VGCCs recorded from a holding potential of -40 mV
during recording solution perfusion (black) and after 10 min insulin perfusion
(gray). F.-G. Compared to time control, recordings from -40 mV, max peak (F)
and late Ca2+ current (G) were significantly reduced by insulin (p<0.05). The
effect of insulin on VGCC does not appear to be L-VGCC selective. All data
represent mean +/- SEM and are normalized to cell size (density, pA/pF),
asterisks indicate significance at the p<0.05 level.

Table 4. Patch clamping parameters.

Group

Cm (pF)

Rm (MΩ)

Ra (MΩ)

HC (pA)

Bath (n=17)

50.8 ± 3.89

432.9 ± 32.0

10.6 ± 0.85

-102 ± 8.6

10 nM Insulin
(n=19)

56.2 ± 3.5

415 ± 34.8

10.7 ± 0.77

-100 ± 8.7

All data presented as means± SEM on measurements of patched neurons
membrane capacitance (Cm), membrane resistance (Rm), access resistance
(Ra), and holding current (HC) (control n= 17, insulin n=19). No significant
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difference was found between control and insulin treated neurons in any
parameters measurements (p>0.05). Comparisons made using unpaired student
t-test.
4.3.2 Effect of insulin on spontaneous Ca2+ transients.
We then used ratiometric Ca2+ imaging to test whether insulin could alter
spontaneous activity in cultured neurons. We used the similar experimental time
frame as presented in Figure 1 and monitored Ca2+ oscillations during 10 min of
Ca2+ imaging solution perfusion (time control; n=11) and during the next 10
minutes when the solution was supplemented with 10 nM insulin (n=14). We
show here that resting Ca2+ levels were not altered by acute insulin exposure
(Figure 2D; p>0.05). Similarly, insulin did not change spontaneous network
activity (no TTX) derived from measures of spontaneous Ca2+ events (Figure 2A
– right). Those include measures of area-under-the curve (AUC; Figure 2 B;
p>0.05), peak amplitude (Figure 2C; p>0.05), and the number of spontaneous
events detected (Figure 2E; p>0.05) in control conditions and in insulin-treated
experiments. These spontaneous Ca2+ transients were blocked by TTX (data not
shown).
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Figure 4.2 Spontaneous Ca2+ transients are not altered in response to acute
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insulin exposure.

A. Example of neurons and ROI selection (green circles and numbered arrowsleft). Right shows the three ROIs measuring somatic Ca2+ across time. This
approach was used to quantify changes during 10 min of imaging solution
perfusion (Time Control) as well as during 10 min of insulin perfusion (Insulin).
B.-E. Insulin perfusion did not change spontaneous Ca2+ activity based on
measures of AUC, peak transient amplitude, or the number of events detected.
Resting Ca2+ levels also were not altered by insulin. All data represent mean
+/- SEM.

4.3.3 Effect of insulin on KCl- mediated Ca2+ transients.
We

used

potassium-mediated

depolarization

(30

s)

in

Ca2+

imaging

experimental conditions to investigate the impact of insulin on overall neuronal
Ca2+ homeostasis. This approach causes membrane depolarization with
subsequent activation of VGCCs and Ca2+ influx through the plasma membrane,
which in turn, activates Ca2+-induced Ca2+-release (CICR) from the
endoplasmic reticulum through activation of RyRs [482-484]. Potassium-induced
Ca2+ transients were reduced by 10 min of insulin perfusion (n=23) compared to
10 min of Ca2+ imaging perfusion (time control; n=14; Figure 3A and B).
Consistent with the results on spontaneous Ca2+ fluctuations, insulin did not
reduce resting Ca2+ levels measured immediately prior to the depolarization
(Figure 3D). While a trend in reduction of the peak Ca2+ transient amplitude was
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noted in response to insulin (Figure 3C; p=0.08), measures of the AUC of the
depolarization envelope unmasked a significant insulin-mediate reduction (Figure
3B; p<0.0001). Notably, the reduction in the potassium-mediated Ca2+ response
seemed to selectively reduce the delayed Ca2+ component or “hump”, present
after the peak response (Figure 3A, bottom right). This brought to our attention a
potential link to CICR, given that this response by nature, is often delayed
compared to an initiating Ca2+ spike.
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Figure 4. 3 Effects of insulin on KCl-induced depolarization.
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A. Pseudocolored images of cells in culture during Fura-2 imaged at rest (left)
and during peak depolarization (right). Red colors indicate greater levels of Ca2+
(higher ratios). Two sequential KCl depolarizations were separated by 10
minutes of either imaging perfusion or insulin. Representative Ca2+ transients
are shown and highlight measures of resting Ca2+, peak Ca2+ and AUC. Note
the selective effect of insulin on reducing the late phase of the Ca2+ transient,
essentially eliminating the “hump”. B. Ratiometric quantification during time
control experiments or after insulin, shows the AUC resulting from KCl-induced
depolarization was significantly decreased by insulin. C.-D. Peak ratio or resting
ratio measures were not altered by insulin. A trend for peak ratio levels in
response to insulin was noted. All data represent mean +/- SEM. Asterisks
indicate significance at the p<0.05 level.
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4.3.4 Insulin appears to reduce CICR function.
To test whether the reduction in the “hump” during potassium-induced
depolarization reflected inhibition of the CICR component, we used high
concentrations of ryanodine (20 uM) which significantly reduce CICR [377, 474].
These experiments required three 30 s repeated potassium depolarizations each
separated by 10 min (time control; Figure 4). To test for the impact of ryanodine
and/ or insulin, the first depolarization was triggered after 2 min of imaging
solution perfusion, the second depolarization occurred after 10 min of ryanodine
perfusion, and the third depolarization was after an additional 10 min of insulin
perfusion (Figure 4A). As shown in Figure 4A and B, blocking CICR with
ryanodine during potassium mediated depolarization (n=10) significantly reduced
the “hump” after the initial high amplitude transient (Figure 4B, F(2,29) = 53.8; p
<0.0001). As consistently shown throughout our studies, time control
experiments show no significant difference in the variables measured (n=11).
Post-hoc analyses revealed no significant difference in the AUC obtained under
ryanodine or insulin conditions. Thus, addition of insulin had no further impact on
this Ca2+ plateau, indicating that high ryanodine concentration may have
occluded the impact of insulin. The lack of an additive effect between insulin and
ryanodine actions suggests insulin may reduce CICR by inhibiting ryanodine
receptors.
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Figure 4.4 Ryanodine receptors are likely targets of insulin actions.

A. Three sequential KCl-mediated depolarizations were used in these
experiments and were triggered under imaging solution perfusion (left) and
during perfusion with ryanodine, or insulin (right). Representative ratiometric
Ca2+ transients highlight the impact of inhibiting CICR on the “hump”. Addition of
insulin did not further reduce the “hump”. B. Quantification across the groups of
cells imaged shows the significant insulin-mediated reduction in the AUC as in
Figure 3. As expected, ryanodine (Rya) also significantly reduced the “hump”,
indicating ryanodine and insulin may both be working on inhibition of RyRs. All
data represent mean +/- SEM. Asterisks indicate significance at the p<0.05 level.
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4.3.5 Insulin actions occur via occupation of the insulin receptor.
To investigate whether 1) components other than insulin in the glulisine
formulation, or whether 2) the actions of insulin were mediated via occupation of
the insulin receptor, we used an insulin binding peptide (i.e., affibody) and an
anti-insulin receptor antibody, respectively. For these experiments, we used the
same experimental protocol as presented in Figure 3 with two potassiummediated depolarization 10 min apart. Either the affibody peptide (n=6-16 per
condition) or the antibody (n=9) was used. The results are again compared to
time controls with perfusion of imaging solution (n=16). While lower doses of the
affibody (100 ng and 500 ng/mL) did not prevent the insulin-mediated reductions
in the Ca2+ AUC (Figure 5A, p<0.01 and p<0.05, respectively), a higher dose (1
ug/ml) was able to completely inhibit this effect such that the reduction in AUC
was no longer present (p>0.05). Doses used are modelled after in vivo studies
[485, 486]. These results suggest that the effects of insulin on hippocampal Ca2+
levels were mediated through insulin receptors (Figure 5B - right).
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Figure 4.5 Anti-insulin affibody peptide and anti-insulin receptor antibody
inhibited insulin actions on KCl-mediated Ca2+ transients.

Experiments were conducted as in Figure 3, with 2 sequential KCl
depolarizations. A. High-dose (1 ug/mL) anti-insulin affibody neutralized the
effect of insulin on KCl-induced Ca2+ transients while lower concentrations (100
ng/mL and 500 ng/mL) did not. B. 500 ng/mL insulin receptor antibody also was
able to inhibit insulin actions on the KCl-mediated Ca2+ transients. These results
indicate the actions reported here on Ca2+ homeostasis are mediated by insulin
working on insulin receptors. All data represent mean +/- SEM. Asterisks indicate
significance at the p<0.05 level.
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4.4 Discussion
The experiments described here were intended to characterize actions of acute
insulin exposure on neuronal Ca2+ currents and Ca2+ levels. The techniques
used provide the most direct approach for analyses on the impact of insulin on
hippocampal neurons without the confounding interactions of blood vessels and
other cell types. Cultured neurons are detached from hormonal and perfusion
influences, providing for a simplified environment where acute drug exposure is
rapid and direct, free from the diffusion hindrance of the brain parenchyma or
extra-neuronal interactions. Similar approaches in our lab and others have
revealed significant connections between the actions of several hormones and
neuronal function [474, 482]. Our results provide evidence that Apidra®, a zincfree insulin formulation, is able to reduce VGCC currents and Ca2+ levels
attained during neuronal depolarization. The mechanism is dependent on insulin
receptor activation, and also appears to engage ryanodine receptors as CICR
contributions were reduced in response to acute insulin treatment.

Ca2+ currents are a target of acute insulin in neurons
The insulin-mediated reduction in whole-cell currents does not appear to be
specific to one subtype VGCC. This is supported by evidence of currents
recorded from -70 mV before and approximately 10 minutes after the addition of
10 nM insulin, showing the same degree of inhibition for the peak and late
currents (i.e., similar inactivation rates in Figure 1A). Furthermore, the reduction
in currents elicited from a holding potential of -40 mV, which favors L-type Ca2+
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currents, was not significantly greater in amplitude when compared to the
inhibition seen from -70 mV, arguing against a selective effect of insulin on L-type
Ca2+ channels. Previous work on regulation of VGCC in different cell types also
notes that the effect of insulin may not be selective for a particular type of VGCC
(e.g., N- or L-type VGCCs; [487, 488].
This insulin mediated reduction in VGCC was not accompanied by a shift in the IV relationship (Figure 1D), indicating the mechanism likely impacts flux of the
charge carrier through the channels rather than alterations in the voltage
sensitivity or inactivation properties of the channels. This result is aligned with
prior

work

in

pinealocytes

and

photoreceptors,

showing

that

tyrosine

phosphorylation can reduce L-VGCC function [335, 407]. Evidence also suggests
that the pore-forming alpha subunit of some VGCCs can be regulated directly by
tyrosine residue phosphorylation [487-489]. Prior work has shown that acute
insulin can alter other ion channels including large-conductance Ca2+-activated
potassium channels (BK-type). Under these conditions, insulin reduced somatic
Ca2+ levels during spontaneous oscillations in cultured hippocampal neurons
[406]. Further, given the evidence that reductions in Src binding to the alpha 1
subunit of the L-VGCC significantly reduces channel current amplitude in cardiac
myocytes [490] and that insulin can reduce Src activity [491], this signaling
pathway likely highlights a potential mechanism by which insulin reduces VGCC
current flux.
Still, it should be noted that some cells respond to tyrosine kinase
phosphorylation with enhanced VGCC function and potentiated Ca2+ levels [492,
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493], and that given the complexity of second messenger systems working
through many kinases and phosphatases [494], the exact impact of insulin on
VGCC likely depends on the presence and state of activation of other interacting
pathways (i.e., PKA, PKC, AKAP, phosphatases, etc.). Irrespective of the
mechanism of inhibition of VGCC by insulin, it is clear that VGCC are a target of
insulin in neurons. The effect described here, therefore, is likely to mediate the
beneficial impact of the hormone on cognitive function following intranasal
delivery in animal models [30, 467, 469, 470] and in early AD subjects [32, 33,
35, 398, 401, 495]. Indeed, according to the Ca2+ hypothesis of aging and
dementia [188, 443, 496], reducing Ca2+ levels in postsynaptic neurons is a
favorable approach to offset cognitive decline in aging and AD (see below).

Other potential targets of insulin actions
Previous work shows insulin can increase cell surface expression of NMDA
receptors [89] and can reduce surface expression of AMPA receptors [88, 332].
These studies employed similar insulin exposure time as used in the current
study, but concentrations were 50-1000-fold higher. Thus, it is not clear whether
transient changes in NMDA and AMPA surface expression would manifest using
10 nM insulin in the absence of TTX. As reported in Figure 2, the nearly
physiological insulin concentration used here does not necessarily alter network
excitability. This is evidenced by a lack of insulin action on resting Ca2+ levels,
peak amplitude of the spontaneous Ca2+ responses, the AUC of the
spontaneous events, as well as the number of spontaneous events. Our work,
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therefore, may suggest that higher concentrations of insulin are needed to alter
network oscillations, overall excitability and spontaneous activity. Although not
tested directly here, our results do not provide evidence that insulin can increase
surface expression of GABAA receptors [92, 405] which should have reduced
excitability. Within the time frame tested here (~10 minutes) and at the low
concentration used, we did not see evidence of depression in spontaneous Ca2+
events (Figure 2). Thus, further studies focusing on insulin concentrationresponses and time of exposure are needed to clarify these discrepancies. Of
course, it will also be important to address the different types of insulin
formulations used and to include the adequate zinc controls, given that almost all
insulin formulations are zinc-based.
While insulin did not alter spontaneous Ca2+ activity and Ca2+ events
amplitudes within the network of cells in culture (Figure 2), we did notice a
significant alteration in the shape of the potassium-mediated Ca2+ responses
following insulin treatment (Figure 3). The disappearance of the “hump” following
the peak Ca2+ rise revealed the possibility that RyRs might be sensitive to
insulin. We tested this hypothesis by pretreating the cultures with high
concentrations of ryanodine to inhibit Ca2+-induced Ca2+ release (CICR). As
shown here, ryanodine pretreatment precluded further insulin-mediated inhibition
of the Ca2+ response to depolarization (Figure 4). This suggests insulin is
capable of reducing CICR likely through tyrosine mediated inhibition of the RyR.
This result is in line with prior evidence that neuronal store-operated Ca2+
channels (SOCCs) responsible for a small but significant secondary Ca2+ entry
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pathway for replenishing the endoplasmic reticulum, are also a target of protein
tyrosine phosphorylation [497]. It should be noted, however, that this result is
contrary to what is seen in striated muscle cells, where insulin elicits an increase
in Ca2+ release through activation of RyR [498]. Future studies are necessary to
identify whether the different RyR subtypes can respond differently to insulin, or
whether these effects are tissue specific, and dependent on particular signaling
pathways.
We suggest that the novel finding of insulin actions on CICR could be highly
beneficial to neurons and to Ca2+ dysregulation seen in aging and/ or AD, and
that this new target potentially offers a secondary level of protection from
sustained Ca2+-related actions in neurons. While it is not clear that the reduction
in the “hump” (Figure 4) may provide a neuroprotective function to neurons, the
insulin-mediated reduction in depolarization observed during this Ca2+ envelope
could well keep neurons engaged during periods of activation.
Learning and memory selective actions of insulin in the brain
Past work studying insulin function in the brain identified critical links to learning
and memory. Whether exogenous insulin on hippocampal neurons worked
through changes in GABA, NMDA, AMPA, or even glucose transporters, it was
understood that insulin could have a specific and selective impact on learning
and memory and conversely, that learning also could have an impact on insulin
receptors [28, 499]. More recent analyses of insulin action provide evidence that
large and diverse areas of the CNS are indeed sensitive to insulin. Previous work
shows insulin is a dynamic hormone with a rich influence on brain function.
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Insulin stimulates the translocation of glucose transporter-4 to plasma
membranes of hippocampal neurons within 15-30 min [100]. This rapid process
is likely to regulate neuronal metabolic demands and the energy needed for
learning and memory processing. In addition, insulin enhances synaptic plasticity
by increasing the expression of dendritic postsynaptic density scaffolding protein
(PSD-95), a key element of postsynaptic junctions in hippocampal neurons [334].
Together these functions and their sensitivity to insulin undoubtedly contribute to
improved encoding of synaptic information for the storage, and perhaps, the
retrieval of memories.
Equally concrete examples of the links between insulin and memory come from
evidence that insulin can acutely reduce the hippocampal AHP, a Ca2+dependent hyperpolarizing potential, which maintains hyperpolarization and
precludes action potential threshold from being reached [30, 380]. The AHP is
larger in aged compared to young animals [184, 379, 433, 453, 476, 500, 501],
thus reducing the amplitude or duration of this hyperpolarizing potential may help
combat age-related memory dysregulation by allowing cells to participate within a
functional network [502]. Indeed, it has been shown that elevating potassium
channel activity impairs learning [503], while lowering L-VGCC reduces the AHP
[432, 452] and enhances learning [432, 504]. Moreover, increasing cholinergic
neurotransmission which enhances cellular excitability also can enhance learning
[436, 505-507].
Still, the evidence of robust insulin actions linked to memory processes or
processes capable of facilitating memory encoding (e.g., metabolism, blood
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flow), does not detract from the traditional role of insulin in homeostasis [508,
509]. Indeed, it is becoming very clear that once insulin in the brain, the hormone
is not limited in function to a single or even a few target areas [366, 510],
strengthening its position as a potential therapeutic target which requires greater
research emphasis.

4.5 Conclusions
We used imaging and electrophysiology techniques to show that zinc-free insulin
could have rapid and selective effects on Ca2+ sensitive functions in neurons,
and that the effects are dependent on insulin activating the insulin receptor
(Figure 5). This clearly engages a series of intracellular signals that through
uncharacterized pathways or mechanisms, lead to rapid Ca2+ reductions during
neuronal depolarization. Clearly, more research will need to be conducted to fully
characterize the mechanism underlying this phenotype and to address the
selectivity of the effect using different insulin formulations. Importantly, we remark
that reducing Ca2+ dysregulation in brain aging, AD and in neuronal cultures has
generally been associated with positive and neuroprotective outcomes, from
improving cognitive functions to reducing cellular toxicity. We present evidence
here that insulin could well be an endogenous modulator of these functions.
Reductions in insulin levels or in insulin signaling in the brain during aging and in
AD may highlight one of the mechanisms that could reduce metabolism, thereby
reducing cognitive function. However, our results also suggest that replacing
insulin or enhancing insulin signaling in the brain of aging, or early AD subjects
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may be a valuable approach. We emphasize that the novel impact of insulin on
neurons presented here could well underline the beneficial impact of intranasal
insulin on cognitive enhancement in the clinic and in animal studies. If insulin is
able to reduce Ca2+ levels in vivo, the noted reductions in insulin-sensitive Ca2+
responses may offset brain aging processes and ultimately, offset the impact of
dementia on brain function.

104

Chapter 5 Discussion and conclusion

The data collected for this dissertation project is presented in the form of two
manuscripts. The purpose was to test the hypothesis that intranasal insulin could
offset cognitive decline in aged animals and to characterize the impact of insulin
on neuronal calcium status. The first manuscript (see chapter two) has been
published in the Journals of Gerontology Series A in 2016 [30] and the second
manuscript (see chapter four) has been submitted to Neuroscience (Maimaiti et
al., 2017).

5.1 Effects of insulin on memory and Ca2+-dependent AHP
In the first study, to test whether intranasal insulin could reverse aging-related
memory decline, we used the Morris water maze, a hippocampal dependent
spatial learning and memory task, to evaluate insulin effects on memory in young
and aged F344 rats. Aged animals were divided into five groups; each group
repeatedly received saline, a low dose of Humalog® and a low, medium, and
high dose of Levemir®. Also, the young control group received saline, used as a
normal young baseline. The behavioral study results showed that intranasal
administration of two different formulations of insulin (Humalog®, a short-acting
insulin analogue, or Levemir®, a long-acting insulin analogue) reversed the
memory decline in aged F344 rats compared to aged rats in the saline controls.
We found that while a low dose of Humalog® and Levemir® enhanced the
memory, a medium dose of Levemir® worsened the memory, and a high dose of
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Levemir® did not change the memory. Therefore, it is clear that selective doses
and formulations of insulin have beneficial effects on the memory in the aged
animals. In addition, controversial clinical study results exist regarding insulin
dosages and formulations for use in AD patients. In animal and clinical studies,
different dosages and formulations of insulin have various outcomes. These
varied results led to further investigation of the underlying mechanisms
responsible for intranasal insulin’s beneficial effects on memory as seen in select
animals and human studies, highlighting the importance of enhancing insulin
action in the brain.
So far, three main methods (insulin sensitizers, intravenous insulin infusion, and
intranasal insulin) have been used for increasing brain insulin levels. Due to the
poor permeability of insulin sensitizer (Thiazolidinedione) to the blood brain
barrier [511, 512], and the high risk of hypoglycemia from intravenous insulin
infusion (see chapter three), however, intranasal insulin appears to be the best
method

to

increase

brain

insulin

levels.

Nevertheless,

the

underlying

mechanisms responsible for intranasal insulin’s positive effects are still poorly
understood. One mechanism responsible for memory decline with aging is
hippocampal Ca2+ dysregulation.
It has been more than 30 years since researchers have focused on Ca2+
dysregulation in the aging brain, which is measured by recording Ca2+dependent afterhyperpolarization (AHP) in the hippocampus neurons. Therefore,
we examined the effects of insulin on Ca2+-dependent AHP, one of the wellknown mechanisms that increases with aging and contributes to memory decline.
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Our results show that treatment of hippocampal slices with insulin reduced Ca2+dependent AHP in hippocampal neurons to the levels seen in young neurons. It
is well documented that Ca2+-dependent AHP (a key biomarker of brain aging)
increases in aged, and memory-impaired animals [30, 184, 377, 379, 380, 432434]. Thus, insulin-mediated reduction in Ca2+-dependent AHP may be
responsible for some of the beneficial effects of insulin on cognition.
Most insulin formulations were designed by combining insulin with zinc. In fact,
zinc itself plays a vital role in the physiological functions of cells, and is like Ca2+,
an essential ion to regulate intracellular signaling. Therefore, it is important to test
insulin and zinc effects separately on brain Ca2+ regulatory processes. Thus,
when the effects of Apidra® (fast acting zinc-free human insulin) and zinc on the
AHP were tested separately, both were found to reduce the AHP. Therefore, we
used the zinc-free human insulin Apidra® to study specific insulin actions in
hippocampal neurons without the influence of zinc.
The next question we asked was how does insulin reduce the Ca2+-dependent
AHP? The greater AHP seen in aged memory-impaired animals positively
correlated with elevated intracellular Ca2+ concentration. This alteration results
from increased Ca2+ influx via voltage-gated Ca2+ channels and Ca2+-induce
Ca2+-release via RyRs (see chapter three). Conversely, it is possible that a
reduction in AHP with insulin treatment may mediate through the reduction in
intracellular Ca2+ levels via VGCCs and RyRs.
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5.2 Whole-cell patch clamping and Ca2+ imaging in hippocampal neurons
In the second manuscript, we aimed to identify the effects of insulin on
hippocampal Ca2+ levels in cultured neurons. The significance of this data is
showing that insulin reestablishes hippocampal Ca2+ homeostasis. Aging and
AD animal models have shown that elevated intracellular Ca2+ levels in the
hippocampus contribute to poor spatial memory [180, 453]. Reestablishment of
intracellular Ca2+ homeostasis might be one of the possible neuronal
mechanisms responsible for the beneficial effects of insulin on cognition. Two
main sources of intracellular Ca2+ are Ca2+ influx through voltage-gated Ca2+
channels on the plasma membrane and internal Ca2+ efflux from the
endoplasmic

reticulum

via

ryanodine-mediated

Ca2+

release

in

the

hippocampus. It is well documented that both voltage-gated Ca2+ channels and
ryanodine receptors undergo functional changes with aging and that lead to
elevated intracellular Ca2+ levels, which is toxic for neurons (see chapter three).
It is widely accepted that reducing the elevated intracellular Ca2+ levels is one of
the established approaches to improving memory in the aging and AD population
[377, 435, 453]. Therefore, insulin effects on both voltage-gated Ca2+ channels
and ryanodine receptors were tested. Insulin affected two main intracellular Ca2+
sources, including Ca2+ influx via voltage-gated Ca2+ channels and RyRsmediated Ca2+ release. After 10 minutes of insulin perfusion to patched single
neurons, whole-cell patch clamp recording results show that both VGCCs and Ltype VGCCs currents decreased in hippocampal neurons. We found that acute
insulin perfusion to neurons resulted in the same level of reduction in both
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VGCCs and L-VGCCs. This data suggests that insulin uniformly affects all type
of voltage-gated Ca2+ channels. It is well documented that an elevated
intracellular Ca2+ results from increased L-VGCCs, which has been linked to
memory decline in aged animals (see chapter three). Therefore, insulin-mediated
reduction in Ca2+ influx via this channel may be an underlying mechanism
partially responsible for insulin’s memory-enhancing effects seen in animal and
clinical studies. In addition, Ca2+ imaging data show that acute insulin perfusion
did not change resting Ca2+ transients, and significantly reduced ryanodinemediated Ca2+ transients. Intracellular Ca2+ concentration is amplified due to
enhanced

ryanodine-mediated

Ca2+-induced

Ca2+-release

from

the

endoplasmic reticulum in animal models of aging and AD [377, 435, 513].
Reduction

in

RyRs-mediated

Ca2+

transients

may

underlie

neuronal

mechanisms responsible for positive actions of insulin in hippocampal neurons.
Furthermore, this result indicates that RyRs inhibitors will improve the memory in
AD patients.

5.3 Insulin improves memory by regulating intracellular Ca2+ levels
Together,

these

two

studies

combine

intranasal

insulin

approaches,

hippocampal-dependent memory and learning task, sharp electrophysiology,
whole-cell patch clamp, spontaneous and depolarization mediated Ca2+ imaging
to highlight potential neuronal mechanisms of insulin-mediated cognitive
improvement seen in clinical studies. We show that hippocampal Ca2+dependent AHP, voltage-gated Ca2+ channel currents, and Ca2+ transients are
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increased in aged rats—all major factors influencing memory decline with
aging—are significantly reduced by insulin treatment. Furthermore, this reduction
in voltage-gated Ca2+ channel currents and ryanodine-mediated Ca2+ transients
were correlated with reversal of Ca2+ dysregulation and memory impairment
observed in aged rats.
These study results support the concept that brain insulin resistance/ deficiency
present in aged, diabetic and AD models of rats could be a major contributor to
aging-related cognitive decline. Indeed, increasing brain insulin levels using the
intranasal route improves memory by reducing AHP via regulating intracellular
Ca2+ levels. Thus, taken together, these findings suggest that insulin is a key
hormone influence over neuronal Ca2+ regulation and strengthen the brain
insulin-deficiency mechanistic hypothesis of pathological aging.

5.4 Aging-related changes in memory and hippocampal Ca2+ levels
Insulin treatment reversed both aged-related memory decline and Ca2+
dysregulation in hippocampal neurons. It has been decades since our lab and
others have focused on the relationship between cognitive decline and increased
Ca2+ dysregulation in aged animals [30, 224, 433, 435, 514]. Ca2+ dysregulation
means elevated intracellular Ca2+ concentration, that gives rise to a larger AHP
in aged animals and is considered one of the neuronal mechanisms underlying
memory decline with aging. In addition, researchers identified pharmacological
agents such as Ca2+ channel blockers (inhibiting the elevation of intracellular
Ca2+ concentration) that reduce the amplitude and duration of the AHP to
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improve cognitive function in aged animals [515]. Furthermore, previous studies
from our research group using gene transfer approaches to increase and/or
decrease FKBP1b (a small immunophilin that stabilizes RyR-mediated Ca2+
release) expression in the hippocampus showed a similar correlation between
memory impairment and Ca2+ dysregulation [435]. In the present study, we
found a consistent association between age-related changes in hippocampaldependent memory, and Ca2+ levels. Most importantly, insulin treatment
improved memory in aged rats, reduced the AHP, Ca2+ channel currents, and
Ca2+ transients. Insulin in the brain may be a key element for maintaining
hippocampal Ca2+ homeostasis and cognitive function during aging.

5.5 Potential relevance to healthy and pathological aging
Biologists suggest that brain function starts to decline from the third decade of life
leading to either healthy or pathological aging, suggesting that some changes in
natural brain aging give rise to pathological neurodegeneration and AD. These
changes include brain insulin deficiency and loss of neuronal Ca2+ homeostasis.
Disruption of brain insulin signaling contributes to the AD clinical symptoms
(memory impairment) and pathology [137, 149]. In addition, increased
intracellular Ca2+ concentration from the dysfunction of VGCCs and RyR
receptors markedly influence neuronal survival, communications, and function,
which have been considered major risk factors for AD [185, 435, 516, 517].
Conversely, brain-specific enhancing insulin signaling improved cognitive
function in selective AD patients, and improved memory in experimental aged
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animals. In addition, our study results show that intracellular Ca2+ levels
decreased with insulin treatment in hippocampal-cultured neurons. Importantly,
brain insulin deficiency during aging together with other factors may accelerate
Ca2+ dysregulation and stimulate amplification of intracellular Ca2+ levels,
increasing the vulnerability of AD. Thus, studies presented here support that
increasing brain insulin levels may be a vital approach for promoting healthy
aging and, possibly, reversing cognitive decline present in aging and AD
populations.

5.6 Study limitations
In the second study, all the whole-cell patch clamping and Ca2+ imaging data
were obtained from the hippocampal cultured neurons in response to acute
insulin treatment. Cells in culture are not expose to same multitude of signals
environment that is present in functional human body. Thus, those data cannot
directly translate into a clinical AD study. However, it provides potential
mechanisms for insulin actions on hippocampal neurons. Primary hippocampal
cultured neurons have been used as a valid model for studying the neuronal
molecular mechanisms underlying the age-related changes in Ca2+ channels
and neuronal survival [439], as well as for visualizing protein expression,
trafficking, and localization [518]. We used primary hippocampal cultured
neurons to study insulin action on hippocampal Ca2+ levels. Intracellular Ca2+
homeostasis is important for proper neuronal function throughout life, and it
influences a wide range of neuronal development processes, including
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formation

of

neurotransmitters,

ion

channels,

neurite

outgrowth,

synaptogenesis, and intrinsic firing patterns [519-522]. Intracellular Ca2+
homeostasis is dependent on the proper function of voltage-gated Ca2+
channels on the plasma membrane and ryanodine receptors on the
endoplasmic reticulum. In addition, both these channels have shown functional
changes during aging. The voltage-gated Ca2+ channel density increases with
aging, and this negatively correlates with neuronal survival in cultured
hippocampal neurons [439]. Hippocampal neurons in the primary culture
undergo time-dependent development and changes as well [183, 523]. From
day in vitro (DIV) 1 to DIV 6, neurons rapidly attach to the dish, grow, and
establish networks. From age DIV 10 to DIV 28, unhealthy and dead neurons
increase as a function of age in the culture. In addition, a whole-cell Ca2+
currents recording from hippocampal neurons at different ages in the culture
show that Ca2+ current density increases as neurons are aged in the culture
[439]. Hippocampal cultured neurons help us to study the effects of insulin on
hippocampal neurons in a single isolated environment that eliminates other
factors. Thus, hippocampal cultured neurons seem to be an appropriate model
for studying the link between insulin and hippocampal Ca2+ levels.
As I mentioned earlier, Ca2+-dependent AHP depends on both Ca2+ and K+
ions. In my dissertation, I focus only on the Ca2+; therefore, the K+ component
still needs to be studied. Therefore, those data partially explain the mechanism
of insulin actions on the AHP and memory.
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5.7 Future directions
These studies have shown that insulin reduces the Ca2+-dependent, K+mediated slow afterhyperpolarization (sAHP), reduces the VGCCs currents, and
reduces RyRs-mediated Ca2+ transients. This study provided a clear link
between insulin and intracellular Ca2+ concentration (mainly through voltagegated Ca2+ channels and RyRs mediated Ca2+-induced Ca2+-release) in
hippocampal neurons. However, the effects of insulin on potassium channels in
hippocampal neurons in the context of cognitive functions have not yet been
studied. There are a few studies showing a connection between insulin and
potassium channels in the kidney [524] but not in the brain. In fact, “Ca2+activated K+ channels play an important role in the control of neuronal
excitability via the generation of the AHP” (Davies et al., 2006). Furthermore,
earlier studies suggest that potassium channels contribute to the generation of
sAHP in hippocampal CA1 neurons [525-529]. In addition, potassium channels
undergo functional changes with aging and influence neuronal function and
sAHP [530, 531]. From these findings arose the idea that insulin may be able to
rebalance potassium channel functions, which may further reduce amplitude
and duration of the sAHP. Other graduate students in the lab could look at the
relationship between insulin and potassium channels in the hippocampal
neurons.
Earlier research intensely focused on RyRs’ role in heart and skeletal muscle
excitation-contraction. Some studies suggest that the cardiac ryanodine
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receptor (RyR2) is a promising drug target for treating arrhythmogenesis [532].
Moreover, RycalsTM is a drug available on the market to inhibit cardiac and
skeletal muscle specific RyRs [533]. In addition, dantrolene, an RyRs blocker, is
a widely used drug to treat malignant hyperthermia in clinic. This dissertation
showed

that

insulin

reduced

the

RyRs-mediated

Ca2+

transients

in

hippocampal neurons. This data suggests that the inhibition of RyRs channels
positively correlates with memory improvement in aged animals. Therefore,
RyRs’ role is not limited to the periphery, but also plays a vital role in the brain in
the context of memory. Specifically, in the hippocampal, RyRs plays an
important role in regulating intracellular Ca2+ levels and maintaining cognitive
function [435, 453]. A few researchers are promoting the idea that
hippocampus-specific RyRs inhibition is a therapeutic target for AD.
Furthermore, this study strongly supports the hypothesis formulated by Dr.
Grace Stutzmann that RyRs blockers are an effective anti-AD therapy. Thus,
RyRs could be a drug target for inhibiting pathological intracellular Ca2+ leaks in
the hippocampal neurons, and, more importantly, for reversing Ca2+
dysregulation

and

memory

impairment
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with

aging

and

AD.
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